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DEFINITION OF KEY TERMS 
Compliance 
Compliance is defined as the extent to which patient’s ‟behaviour coincides with medical 
advice on how to take tuberculosis treatment” (Pandit & Chaudhary 2006:241). Although 
compliance and adherence have been used interchangeably, looking at the definition of 
adherence which is generally defined as the “the extent to which a patient follows the 
prescribed treatment regimen” (Farmer, 1999: 1074), the study has taken an approach of 
using the term compliance. In this study, compliance aims at looking at the actual percentages 
of the prescribed medications taken, factors involved in treatment taking that influence the 
actual taking of medications and the effectiveness of medications which is determined by 
treatment outcomes. This is considered different from adherence that generally assess 
whether the treatment regimen was followed and if medications were collected without   
further assessment on whether the medication was actually taken or not or whether it was 
effective. 
Cured 
Smear positive patient converted to smear negative in the last month of treatment and on at 
least one previous occasion (WHO, 2007). 
Defaulter 
A defaulter refers to a patient who interrupted TB treatment for two consecutive months 
during their treatment period (WHO, 2007).  
Died (TB mortality) 
These are the patients who died for any reason during the course of treatment (WHO; 2007). 
DOTS supporter 
A person who observes TB patients swallowing the medicines (WHO; 2007). 
Transferred out 
Patients who are transferred to another facility and whose treatment outcome is unknown 
(WHO; 2007). 
Treatment completed 
These are patients who have completed 6 months of treatment but who does not have a 
negative smear or culture results in the last month of treatment and on at least one previous 
occasion (WHO, 2007). 
Treatment failure 
A patient who is sputum smear positive at five months or at the end of 6 months treatment 
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(WHO; 2007). 
Treatment outcomes 
According to the WHO (2007), treatment outcomes are described as the end product of TB 
treatment. The following outcomes are possible: patients who are cured; completed treatment; 
died (TB mortality); failed treatment; defaulter and those who are successfully treated.  
Treatment success 
These are patients who are cured and have completed their 6 months of treatment (WHO, 
2007). 
Treatment success rate 
This is defined as the proportion of TB patients who have been successfully cured and those 
who completed treatment over a specified period of time (WHO, 2007). 
Tuberculosis 
Tuberculosis (TB) as defined by the World Health Organization (WHO) (2011) is an 
infectious disease which is caused by the bacillus Mycobacterium tuberculosis that mainly 
affects the lungs PTB (pulmonary tuberculosis) although it also affects other sites of the body 
(extra pulmonary tuberculosis). 
Multi-drug resistant TB 
A type of TB which is considered resistant to at least isoniazid and rifampicin (Newell et al., 
2006). 
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ABSTRACT 
 
Tuberculosis (TB) is a major health problem worldwide, with an estimated 9 million new 
cases accounting for an estimated 1.5 million deaths in 2012. Non-compliance with TB 
treatment has become a major barrier to achieving global TB control targets. Namibia is one 
of the worst affected countries in Africa with a high case notification rate (CNR) of all forms 
of TB and relatively low treatment success rate compared to the WHO targets. 
 
The study aimed at investigating TB treatment compliance and measuring its association to 
patient characteristics and treatment outcomes, in determining the effects of compliance on 
treatment outcomes in Windhoek District. This information is crucial for TB programme 
management and development of targeted strategies.  
 
A quantitative observational analytic study using a retrospective cohort design was adopted. 
New adult Pulmonary Tuberculosis (PTB) patients treated under DOTS in Windhoek District 
between 1st January 2013 and 31st December 2013 were included in the study based on 
specified criteria. Data was collected from the patients TB treatment cards using an extraction 
tool. Selection and information bias was eliminated by using clearly defined inclusion and 
exclusion criteria using a pre-tested standardised tool. Statistical analysis using descriptive 
and analytic statistics was done using Epi Info 7 to determine compliance, treatment 
outcomes and to measure the associations.  
 
Overall treatment compliance (89%), initial phase compliance (97.2%) and continuation 
phase compliance (88.1%) were reported in the study. Age (OR=4.3 95% CI (1.72 – 9.90), p-
value=<0.01) and type of area (OR=0.02 95% CI (1.00 – 1.13), p-value=0.05) were 
associated with compliance in the continuation phase. Overall, type of area (OR=0.03 95% 
CI (0.00 – 0.91), p-value=0.04) remains associated with treatment compliance. Treatment 
success is reported among 86.1% of patients. Poor treatment outcomes are associated with 
non-compliance in the initial phase ( =49.98, p-value=<0.01), continuation phase 
( =98.81, p-value=<0.01) and overall ( =110.02, p-value=<0.01). 
 
Overall treatment compliance (89%) although higher than expected was lower than the WHO 
recommended 90% compliance. Very high compliance (97.2%) were reported in the initial 
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phase of treatment whilst compliance was also lower than desired (88.1%) in the continuation 
phase. Non-compliance recorded in the continuation phase is in agreement with the literature. 
Age and type of area are associated with compliance as reported in the continuation phase 
and overall in this study is new contribution of knowledge. The findings suggest that 
treatment compliance is associated with treatment success in both phases of treatment and 
overall. Low compliance especially in the continuation phase could lead to poor treatment 
outcomes such as prolonged infections, relapse, high TB mortality and drug resistance 
leading to increased programme costs. The study concludes that non-compliance results in 
poor treatment outcomes highlighting the need for interventions that address compliance in 
all phases but specifically within the continuation phase and amongst those at risk of having 
reduced compliance such as those in rural areas and young adult patients aged (15 – 34 
years). Recommendations to the District Management Team and TB Programme Managers 
include: identification of measures that promote treatment compliance; support and 
monitoring of TB patients’ compliance continuously; strengthening CB-DOT by increasing 
CB-DOT points and enhancing CB-DOT supporters’ capacity as well as strengthening record 
keeping as a monitoring tool to increase compliance and improve treatment outcomes. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Overview of TB 
 
Tuberculosis (TB) is a major health problem worldwide, with an estimated 9.0 million new 
cases reported in 2013 accounting for an estimated 1.5 million deaths in the same year. These 
reported cases and deaths are unacceptably high considering the fact that TB is preventable 
and curable (WHO, 2013). Of all the reported cases in 2013, 25% were in Africa and TB was 
reported to be the second leading cause of death in sub-Saharan Africa despite the availability 
of effective treatment (WHO, 2013; Stop TB Partnership, 2006). Africa is not on track for 
achieving the global TB mortality and prevalence targets and this may be attributed to 
resource constraints, conflicts and instability, as well as the widespread Human 
Immunodeficiency Virus (HIV) epidemic. The progress towards reaching the global targets is 
further affected by treatment defaulting and poor treatment compliance (Bam et al., 2005). 
About half of the patients diagnosed with TB globally do not complete their treatment and 
this has the potential for negative treatment outcomes such as prolonged infectiousness, 
treatment failure, drug resistance, relapse and death (Bam et al., 2005; Newell, 2006; WHO, 
2003).  
 
Namibia is one of the most affected countries in Africa, as shown by the very high case 
notification rate (CNR) of all forms of TB. About 11 145 cases were notified in 2012, 
equivalent to a CNR of 529 per 100,000 population. TB is widely dispersed in Namibia 
although its distribution varies by region. TB incidence in Namibia is increased through HIV 
as reflected by the HIV prevalence of 50% among TB patients as reported in the 2012-2013 
annual TB report (MoHSS, 2013).  
 
The country reported a TB treatment success rate of 83% in 2012, which is below the global 
target of 90% with a defaulter rate of 5%, treatment failure of 5% and mortality related to TB 
at 5%, while 2% of the patients were reported as transferred out (MoHSS, 2013). The 2012-
2013 annual TB report (MoHSS, 2013) further reported an increase in the number of notified 
cases of drug-resistant TB (DR-TB) in the country from 2007- 2012.  
 
TB treatment in Namibia is offered free of charge along with prevention, promotion and 
rehabilitation services and other services such as antenatal care, growth monitoring 
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promotion, immunization for children under 5 years as well as psychiatric treatment and anti-
retroviral treatment (ART) (MoHSS, 2009). 
 
Despite the continued efforts to control TB and eliminate it as a public health threat, Namibia 
continues to experience alarmingly high rates of TB. There are also reported cases of 
defaulters, treatment failure and TB related mortality. These challenges pose a problem to the 
effective implementation of the TB control programme (MoHSS, 2013). 
 
1.2 World Health Organisation and TB control 
 
In its efforts to control the burden of TB that prevails in many low and middle income 
countries and poses a major public health problem, the World Health Organisation (WHO) 
revived its global effort in 1991 through the development of the Directly Observed 
Treatment-Short course (DOTS) strategy (Raviglione and Pio, 2002; WHO, 2006). The 
DOTS strategy was developed by the WHO as a response to the inappropriate use of the basic 
medical technologies for proper diagnosis and treatment of TB in most parts of the world 
(Raviglione and Pio, 2002).  
 
The WHO deemed the DOTS strategy appropriate for addressing the basic care elements 
needed for effective delivery of such technologies. One of the basic elements of the DOTS 
strategy is to ensure that there is standardised short-course chemotherapy in the management 
of all TB cases that should be administered under proper case management conditions that 
include Directly Observed Treatment (DOT) (MoHSS, 2010; Raviglione and Pio, 2002). This 
strategy was considered a reliable measure to ensure that patients are taking their TB 
medicines as prescribed in order to enhance patient adherence, reduce treatment interruption 
and improve treatment success (Raviglione & Pio, 2002). Therefore, DOTS treatment is 
administered to TB patients for the whole treatment duration in enhancing patients’ 
adherence, reducing treatment interruption and improving treatment success (Raviglione & 
Pio, 2002; WHO, 2006). TB treatment is administered in two phases: the initial (intensive) 
phase, which is the first two months of treatment and the continuation phase that constitutes 
the last 4 months of treatment (WHO, 2006). 
 
In the intensive phase patients are treated with four or more medicines Isoniazid, Rifampicin, 
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Pyrazinamide and Ethambutol (HRZE). These medicines are administered as a daily DOT for 
two months, to ensure that the majority of TB bacilli are killed and resistant bacilli have no 
chance of surviving. While in the continuation phase, patients are treated with fewer TB 
medicines Isoniazid, Rifampicin and Ethambutol (HRE) for 4 months because the population 
of live TB bacilli becomes smaller and the likelihood of containing resistant mutants is very 
small but these medicines are also provided as a DOT treatment. For all new TB patients, the 
DOT is recommended for the first two months of treatment and preferably for the full 6 
months course (MoHSS, 2009; WHO, 2003). For patients on re-treatment the DOT is 
recommended for the full duration of treatment which is 6 - 9 months (Stop TB Partnerships, 
2006; WHO, 2006). 
 
Since DOTS is recommended for the entire treatment course, its implementation requires a 
patient-centred approach. Therefore TB treatment via the DOTS is organized in a way that it 
is accessible and affordable to all patients and their treatment supporters who are referred to 
as DOTS supporters. (MoHSS, 2009; WHO, 2006). The DOTS observations takes place at 
health facilities which is referred to as health facility-based DOT and at the community level 
which is known as community-based DOT (CB-DOT). Health facility-based DOT is 
provided at the health facility situated conveniently close to the patient’s home or workplace. 
Patients are required to take their medications daily under the observation of the health care 
workers. Whereas CB-DOT has various options that include: workplace DOT, guardian-
based DOT and community health worker-assisted DOT. Workplace DOT is either provided 
by the health worker at the workplace or by the lay person. While guardian-based DOT is 
provided by the lay person selected by the patient from his/her house or neighbourhood who 
is willing to take responsibility for the patient’s TB treatment. Community health worker-
assisted DOT is provided at the patient’s house or at any agreed place by the community 
health worker  in the neighbourhood of the patient, who takes responsibility for the patient’s 
daily DOT (MoHSS, 2009; WHO, 2006).  
 
After a decade of the DOTS implementation globally, another strategy which is an addition to 
DOTS strategy was launched in 2006. The Stop TB Strategy was launched with the aim of 
responding to or addressing the many challenges that could not be addressed by  DOTS, 
particularly the challenges of drug-resistant TB, frail health systems, insufficient stakeholder 
(private provider and community) engagement as well as dependence on flawed medical 
technologies (Stop TB Partnerships, 2006; WHO, 2006). The Stop TB Strategy further aimed 
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at halving TB prevalence and TB related mortality reported in 1990 by 2015. This was to be 
done through the following components: pursuing high quality DOTS expansion and 
enhancement; addressing TB-HIV, MDR-TB and the needs of poor and vulnerable 
populations; health system strengthening; engaging all care providers; empowering TB 
patients and communities through partnerships and enabling and promoting research (Stop 
TB Partnerships, 2006; MoHSS, 2009; WHO, 2006). The Stop TB Strategy set the treatment 
success rate at 90% (WHO, 2006). 
 
Enhanced TB treatment through the DOTS strategy and the Stop TB Strategy have saved 
many lives worldwide as their successful implementation has been associated with reduction 
in TB incidence and improved treatment outcomes in countries such as Peru, Cuba, and 
China, in some parts of India and in the USA (Lönnroth et al., 2009). However, studies have 
shown a worrisomely slow decline in TB burden and treatment success in sub-Saharan Africa 
and some parts of Europe. In Africa in the early 1980s and 1990s, the slow decline in TB 
burden has been attributed to the rapid increase of HIV (Lönnroth et al., 2009). According to 
the WHO (2013), there are still about 1000 or more cases per 100 000 people reported in 
South Africa and Swaziland in 2012 which is a strong indication of high TB burden in sub-
Saharan Africa. Treatment success is reported by the WHO (2013) to be at its lowest in 
Europe with only 75% of all new cases successfully treated. However, Africa has also 
reported low treatment success rates in South Africa and Nigeria. . The low treatment success 
in Europe and Africa is mostly attributed to non-compliance with TB treatment (WHO, 
2013).  
 
1.3 TB control in Namibia 
 
In Namibia, TB is managed through both the DOTS and the Stop TB Strategy as 
recommended by the WHO. DOTS has been adopted and implemented in Namibia from 1995 
and was rolled out throughout the country by the end of 1996. DOTS is implemented at 
health facilities (health facility-based DOT) and at the community level (CB-DOT). Patients 
are observed swallowing the medicines by either the health care worker or any other person 
who has assumed co-responsibility for the patient’s TB treatment for the entire treatment 
period, and these people that observe patients taking their treatment are referred to as DOT 
supporters (MoHSS, 2009). However, CB-DOT has not reached all the areas due to the 
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vastness of the districts and inadequate CB-DOT supporters both in terms of the number and 
expertise (MoHSS, 2009; MoHSS, 2010; MoHSS, 2013).  
  
The Stop TB Strategy in Namibia was adopted and implemented in 2006 with the aim of 
complementing the DOTS effort. Through this new strategy, the TB prevalence and TB 
related mortality were expected to be lowered through: pursuing high quality DOTS 
expansion and enhancement; addressing TB-HIV, MDR-TB and the needs of poor and 
vulnerable populations; health system strengthening; engaging all care providers; 
empowering TB patients and communities through partnerships and enabling and promoting 
TB related research (MoHSS, 2009). The introduction of the Stop TB Strategy has seen a 
decline in TB prevalence and TB mortality in the country. In 2012, Namibia reported 11 145 
cases equivalent to a CNR of 529 per 100 000 population. In 2007, 2008, 2009, 2010 and 
2011, the country reported 15 244, 13 737, 13 332, 12 625 and 11 924 cases equivalent to 
CNR 722, 665, 634, 589 and 545 respectively. This represents a decline in TB prevalence, 
compared to the 11 145 cases reported in 2012, which translates to a CRN of 529 per 100 000 
population. Maintaining the downward trend observed since 2007, TB related mortality 
declined from 8% reported in 2007 to 5% in 2012 (MoHSS, 2013). Though there is a 
downward decline in TB prevalence and mortality observed in the country, TB treatment 
success of 83% reported in 2012 remains lower than the WHO recommended TB treatment 
success of 90%. 
 
TB services are offered by various categories of health care workers namely: doctors, nurses, 
field promoters and home-based care workers. The doctor’s role is mainly limited to the 
diagnosis and management of TB complications. While nurses are the cornerstone of TB 
management and treatment as they are responsible for ensuring that the patients complete 
their treatment successfully. Field promoters are lay persons from the community who may 
be attached to the health facility or to other TB treatment points in the community and they 
have been trained on TB-DOT and TB case finding. Their roles are to provide support to the 
TB nurses regarding information, education and communication (IEC), observation of 
treatment, recording and tracing of patients who interrupt treatment. Community-based health  
care workers play the role of TB case-finding and CB-DOT as they are situated in the 
community and they act as DOT supporters for community health care worker-assisted DOT. 
Doctors and nurses are available at health facilities while field promoters and home-based 
care workers are only available at the clinics and in the community respectively (MoHSS, 
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2009).  
 
Inadequate compliance with TB treatment has negative effects on TB control and has in most 
instances led to drug resistance and further spread of TB in the communities. This increases 
TB morbidity and mortality (Adane et al., 2013; Amuha et al., 2009; Naidoo et al., 2013). 
Therefore, increasing the effectiveness of the TB control strategies requires efforts that will 
optimize compliance with treatment and thus improve treatment success and ensure better 
treatment outcomes. That can be achieved if the compliance and the relationship between 
compliance and patient characteristics as well as treatment outcomes are known. This will 
enable the determination of the effects of treatment compliance on treatment outcomes. 
Acquiring such knowledge will enable targeted strategies to be devised. 
 
1.4 Problem Statement 
 
Despite significant efforts to control TB, and regardless of the availability of free and 
effective treatment, TB remains a major health problem and the second primary cause of 
death in Namibia (MoHSS, 2013). Windhoek District being ranked at number one on the 
disease burden in the country, reports the equivalent of 17% (1932 cases) of all reported TB 
cases in the country and a case notification rate of 567/100 000 population in 2012 (MoHSS, 
2013). The district also recorded the highest mortality in the country, 4% of TB patients in 
the district. Though the DOTS strategy was implemented to enhance patient adherence, 
reduce treatment interruption and improve treatment success rates, there are still reported 
cases of default, treatment interruption and low rates of treatment success (MoHSS, 2009; 
MoHSS, 2013). Compliance with TB treatment in Namibia is not known as there is no 
information documented in the Namibian TB programme on how their patients comply with 
TB treatment. Thus the factors affecting TB treatment compliance as well as the effects of 
treatment compliance on treatment outcomes are not known in Windhoek District and 
Namibia at large because they were never explored. There are also very few studies that 
assessed compliance in Namibia that only explored the factors influencing compliance in 
general but not in the phases of treatment. Therefore this study attempts to investigate TB 
treatment compliance and measure the relationship between compliance and patient 
characteristics in different phases of treatment and overall as well as treatment outcomes in 
order to determine the effects of treatment compliance on treatment outcomes in the 
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Windhoek District. 
 
1.5 Significance of the study 
 
This study will provide insights into the overall TB treatment compliance and in the different 
phases of treatment, association of compliance across a range of patient characteristics as 
well as assess the relationship between treatment compliance and treatment outcomes. This is 
useful in determining the effect of treatment compliance on treatment outcome in Windhoek 
District. The information will contribute to the existing body of knowledge and provide new 
context specific information on TB management in the Windhoek District with possible 
lessons for other Namibian settings. The knowledge is crucial to TB programme management 
especially District Managers and service planners in developing targeted strategies to 
increase compliance and improve treatment outcomes. Moreover, those strategies are crucial 
to improving and increasing TB treatment success (cure and treatment completion) in the 
district through the promotion of compliance with TB treatment by TB patients in order to 
prevent TB defaulting, treatment failure, resistance and TB mortality.  
 
1.6 Study outline 
 
The report is presented in 6 Chapters.   
 
Chapter 2 focuses on the review of the relevant literature pertaining to TB treatment 
compliance and its effects on treatment outcomes. 
 
Chapter 3 describes the research methods used in the study with the specific focus on aims 
and objectives, type of research and design, study population, study setting, sampling 
procedure study variables, data collection methods, measures to prevent bias and ensure 
validity and reliability, statistical analysis and ethical considerations involved in the study.  
 
In Chapter 4, the study findings will be presented. While Chapter 5 discusses the findings of 
the study. 
  
The final Chapter addresses the conclusion and recommendations.  
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CHAPTER 2: LITERATURE REVIEW 
 
Introduction 
 
Tuberculosis is a major health problem worldwide, with more new cases reported yearly and 
an increase in TB mortality (WHO, 2013). According to Bam et al. (2006), non-compliance 
with TB treatment is one of the major barriers in achieving global TB control targets in most 
parts of the world regardless of strategies put in place globally to control TB. About half of 
the patients diagnosed with TB do not complete their treatment and this results in negative 
treatment outcomes such as prolonged infectiousness, drug resistance, relapse and death 
(Bam et al., 2006; Newell et al., 2006; WHO, 2011). This study is trying to determine the 
effects of treatment compliance on treatment outcomes for new PTB patients treated via 
DOTS in Windhoek District in Namibia.  
 
This Chapter provides information on the purpose and scope of this review, a review of the 
literature pertaining to TB treatment compliance and its effects on treatment outcomes. It 
starts with the review on the importance of treatment compliance in TB management. 
Consequently, the review on compliance with DOTS TB treatment with a description of how 
TB treatment compliance is defined and measured elsewhere will also be presented. The 
review will also provide a summary of the existing evidence of treatment compliance among 
different treatment strategies as well as the associated TB treatment outcomes in such 
strategies. Factors influencing treatment compliance through the DOTS strategy will also be 
presented. The review will conclude by highlighting some of the gaps in knowledge 
regarding the effects treatment compliance has on different treatment outcomes. 
 
2.1 Purpose of the literature review 
 
The purpose of this literature review is to organise and systematically present what is known 
about TB treatment compliance by looking at what has already been studied and published in 
order to avoid unnecessary replication of information which wastes resources (Burns & 
Grove, 2005). Reviewing the relevant literature on TB treatment compliance and its effects 
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on treatment outcomes for PTB patients in various contexts is essential in validating and 
justifying the significance of this study. 
 
2.2 Scope of literature review 
 
In determining the effects of treatment compliance on treatment outcomes for PTB patients in 
Windhoek District in Namibia, the literature review has made use of the readings from 
different sources. Institutional reports, WHO materials, academic theses and articles from 
journals were reviewed. Information from African countries was relied on more as most 
African countries are similar to Namibia thus their information resonates with the Namibian 
context. Few studies from countries elsewhere were also included since TB treatment 
compliance is a worldwide concern. Since the terms compliance and adherence have been 
used “interchangeably in the past” (Farmer, 1999: 1074), both terms were considered in 
selecting and reviewing the relevant literature. 
 
2.3 Literature reviewed 
 
Numerous studies have been conducted worldwide to try and explore compliance with TB 
treatment via DOTS. Information on the importance of treatment compliance, compliance 
with DOTS treatment, treatment compliance among different treatment strategies, treatment 
compliance and associated treatment outcomes in different treatment strategies and factors 
influencing DOTS treatment compliance is presented below. 
 
2.3.1 Importance of treatment compliance in TB management 
 
Compliance with prescribed anti-TB treatment has many beneficial roles to play in TB 
control programmes especially programmes that fall under the DOTS strategy. In many TB 
programmes, treatment compliance has been associated with high TB cure rates and 
reduction in the emergence of drug resistance (Adane et al., 2013; Afns & Ji, 2010; Naidoo et 
al., 2013). Therefore correct and consistent compliance among TB patients receiving 
treatment through DOTS is required throughout the treatment period in order to achieve good 
treatment outcomes which is key to achieving high cure rates (Naidoo et al., 2013).  
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Compliance requires patients to take their TB treatment in a regular and consistent way in 
order to reduce the risk of treatment failure, relapse and development of drug resistant strains. 
According to Afns & Ji (2010), interruptions that occur especially in the early stages of 
treatment can cause an increase in the TB transmission rate. This is because the initial stage 
of treatment is regarded as the most infectious stage with many TB bacilli. This is also the 
stage where resistant bacilli survive if not properly treated, therefore it requires correct and 
consistent administration of medication in order to ensure that the majority of TB bacilli are 
killed and resistant bacilli have no chance of surviving. To prevent the increase in TB cases 
and the emergence of drug resistant TB, patients need to be encouraged to comply with their 
TB medication (Adane et al., 2013; Brust et al., 2010). 
 
Non-compliance with TB treatment still poses a challenge in most TB control programmes 
(Adane et al., 2013; Amuha et al., 2009; Naidoo et al., 2013; Shargie & Lindtjørn, 2007). In 
Uganda and Ethiopia, like in other many countries in sub-Saharan Africa, poor compliance 
with TB treatment among patients with TB was reported to be a major problem (Adane et al., 
2013; Amuha et al., 2009). In a cross-sectional study done in South Africa by Naidoo et al. 
(2013) on predictors of TB and ARV adherence, the authors argue that poor adherence with 
treatment was strongly associated with low cure rates of TB. 
 
Studies further indicate that poor and inconsistent adherence like non-adherence have 
negative effects on TB control, and has in most instances led to drug resistance and further 
spread of TB in the community which increases morbidity and mortality (Adane et al., 2013; 
Amuha et al., 2009; Naidoo et al., 2013).  
 
Many TB programmes have reported an increase in the health care costs related to the 
negative effects of non-compliance. Therefore, patients with TB are expected to have 
adherence of greater than 90% if they are to be cured (Adane et al., 2013; Amuha et al., 
2009).  
  
2.3.2 Compliance with DOTS TB treatment  
 
Compliance with DOTS TB treatment is required if good treatment outcomes and treatment 
success that includes cure and treatment completion are to be achieved. According to 
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Awofeso (2008), TB treatment requires a treatment compliance of greater than 90% as 
recommended by the WHO in order to facilitate cure and to ensure treatment success. This 
was also indicated by Adane et al. (2013), Amuha et al. (2009) and Takarinda et al. (2012). 
Patients who took 95% of their prescribed medications were found to show high compliance 
while those who adhered for 40% and below demonstrated a low compliance in a study by 
Awofeso (2008).  
 
Dye et al. (2005) indicated that treatment compliance has been commonly considered to be 
taking at least 80% of the prescribed treatment. This definition of compliance is consistent 
with the definition of non-compliance in a study conducted in Siberia that assessed barriers to 
successful TB treatment in Tomsk, where non-compliance was considered for all patients that 
missed 20% or more of the prescribed doses during the treatment period (Gelmanova et al., 
2006).  
 
In a study done in Uganda by Amuha et al. (2009) on non-adherence with anti-TB 
medications by TB/HIV co-infected patients, non-adherents were considered as patients that 
missed more than 10% (taken less than 90%) of the TB medication in five days preceding the 
survey. Adherence in this study was measured through a recall by the patients and it was 
calculated as the percentage of prescribed medications over five days that the patient has 
taken (Amuha et al., 2009). In a study by Bam et al. (2006) patients were deemed non-
compliant if they missed more than 7 consecutive days of treatment in their entire treatment 
duration. Other studies that looked at compliance defined non-compliance as missing more 
than two consecutive months of treatment (Castelnuovo, 2010) and missing one dose in four 
days which is considered 25% of dose missed (Adane et al., 2013).  
 
From the above discussion, it is clear that compliance has been defined and measured 
differently in different contexts, which poses a bit of a challenge to comparing compliance 
between different contexts. In a review conducted about compliance with anti-TB treatment 
in sub-Saharan Africa, the proportion of patients defaulting from treatment varied by phase of 
treatment from 11.3% in the initial phase to 29.6% in the continuation phase. Although the 
findings revealed a high rate of non-compliance, this non-compliance was limited to those 
patients that defaulted (missed two consecutive months of treatment), but did not assess other 
non-compliance. The author further acknowledged the heterogeneity in information and 
difference in the definition of compliance in the papers reviewed that prevented meta-analysis 
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to be performed. Thus the study could not confidently draw conclusions about the reasons for 
this high non-compliance, nor the effects of compliance on different treatment outcomes 
(Castelnuovo, 2010).  
 
In the Ugandan study mentioned above, the prevalence of non-compliance with anti-TB 
treatment was 25% and non-compliance was more likely to be reported in the continuation 
phase than in the initial phase of treatment (Amuha et al., 2009). A cross-sectional study done 
in Gambia by Afns and Ji (2010) comparing health facility DOTS among TB patients before 
and after the introduction of daily DOTS also found that the majority of patients defaulted in 
the continuation phase of treatment because in that phase most of their main symptoms 
disappeared. These findings suggest that the continuation phase is the most problematic phase 
of treatment when it comes to compliance with TB treatment.  
 
An institution-based cross-sectional survey conducted among TB patients in Ethiopia 
indicated non-compliance of 10% and 13.6% for patients assessed over a month and those 
assessed over four days respectively. The study further revealed that patients in their 
continuation phase of TB treatment were about seven times more likely to be non-adherent 
compared to the patients in the initial phase treated through DOTS (Adane et al., 2013). In a 
household survey conducted in Zambia by Kaona et al. (2004) non-compliance was recorded 
at 29.8%, and the study also indicated the continuation phase of treatment as the phase in 
which most treatment interruption occurs. 
 
The findings of non-compliance being common in the continuation phase of treatment is 
consistent with Castelnuovo's (2010) findings; however this study only assessed one month 
compliance and did not look at the whole treatment duration which might have produced 
different findings. Compliance in this study was measured over the four days preceding the 
survey and all the patients that missed at least one dosage (25%) out of four doses were 
considered non-compliant (Adane et al., 2013) The study further acknowledged that DOTS 
with daily supervision for the whole treatment duration though yielding good results, could 
be a challenge for most patients, especially those co-infected with HIV that also require 
regular visits to ART clinics to collect their medications (Adane et al., 2013).  
 
A cross-sectional study done in Tanzania by Mkopi et al. (2012) on adherence to TB therapy 
among patients receiving home-based DOT which is part of community-based DOT recorded 
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adherence of 75%. However adherence in this study was only measured at one point in time, 
thus the study recommends a cohort study to assess the rate of adherence throughout the full 
treatment course. This is deemed necessary in identifying the treatment phase that requires 
more support when it comes to treatment compliance (Mkopi et al., 2012). 
 
This study has adopted the WHO recommended of compliance, whereby high compliance 
will be considered as patients that have taken 90% or more of their prescribed TB 
medications, while low compliance will be considered for all the patients who missed at least 
40% of treatment. Those that have taken between 40% and 90% will be considered average 
compliance (Awofeso, 2008; Dye et al., 2005). Both average compliance and low compliance 
will be measured as non-compliance in this study. The study has taken this approach taking 
into consideration that it is the WHO recommendation, and there are a number of studies that 
have used the same approach that will enable comparisons to findings from different settings. 
 
To summarise the above discussion, the WHO require a TB treatment compliance of greater 
than 90% in facilitating cure and achieving treatment success. Compliance has been defined 
and measured differently in different settings, but most of the studies have adopted the WHO 
recommendation. Compliance with TB treatment has been reported to be low in most studies, 
with the continuation phase of treatment identified as the most problematic phase when it 
comes to treatment compliance and one study recommending a cohort study to look into the 
rate of compliance. A WHO recommended compliance is adopted in this study to enable 
comparisons of the findings in different settings. 
 
2.3.3 Treatment compliance across different treatment strategies 
 
As mentioned in the introduction (Chapter 1), treatment via DOTS in Namibia is 
administered through different strategies namely: community-based DOT and health facility-
based DOT. However, some TB programmes elsewhere are still offering TB treatment via 
self-administered treatment.  
 
A cross-sectional study done in Gambia by Afns and Ji (2010), revealed compliance among 
patients treated via self-administered treatment and the patients treated with fixed-dose via 
DOTS. The findings indicate that those patients that received daily medication with fixed-
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dose via DOTS were more likely to comply with their TB treatment because patients 
considered that option to be convenient for them. However, the study did not indicate the 
type of DOTS used in administering the fixed-dose, neither did it indicate how patients 
complied with their treatment in the initial and continuation phase of treatment (Afns & Ji, 
2010).  
 
A United States of America (USA) based retrospective study by Jasmer et al. (2004) 
compared treatment compliance among TB smear positive patients treated under DOTS and 
those treated through self-administered therapy. Similarly to the findings from the Gambian 
study, this study has also indicated that those patients treated through self-administered 
therapy had a high risk of non-compliance with the treatment regardless of the different 
methods used (Jasmer et al., 2004). 
 
A review by Volmink & Garner (2007), compared treatment completion by TB patient 
treated through DOTS administered by health workers, family members, volunteers and those 
self-administering of treatment. The review did not find any statistical difference in treatment 
completion between the range of DOTS and self-administered treatment. However, the study 
did not indicate how patients complied with treatment on different types of DOT compared to 
self-administration. Thus, this review could not provide evidence for compliance on different 
types of DOTS and self-administration (Volmink & Garner, 2007). 
 
A longitudinal study done in Tanzania by Van Den Boogaard et al. (2009) assessed 
adherence to community-based DOTS among the TB patients. The study findings indicate a 
high compliance of 96.3% among the patients treated under community-based DOT. 
Similarly, very high compliance  (100%) were recorded in a study done in Iraq by Niazi and 
Al-Delaimi (2003) on the impact of community participation on treatment compliance and 
outcomes for TB patients treated via DOTS compared to health-facility based DOTS that 
recorded 14% compliance. 
 
As revealed by the above discussion, most studies that compared TB treatment among 
different strategies did not indicate how patients complied with their treatment and some did 
not indicate the type of DOT used however few studies have indicated that compliance was 
higher among community-based DOT. 
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2.3.4 Treatment compliance and associated TB treatment outcomes in 
different treatment strategies 
 
According to a study done in Tomsk, Russian Federation on the barriers to successful TB 
treatment by Gelmanova et al. (2006), non-compliance with TB treatment was identified to 
have significant adverse effects for the outcomes of TB treatment. The study classified 
treatment outcomes as good or poor. Good treatment outcomes were generally considered to 
be those patients who are cured and who completed their treatment, while poor treatment 
outcomes are considered those patients that defaulted, whose treatment failed and those that 
died while on TB treatment. About 66% of all poor outcomes experienced in this study 
occurred among those patients that did not comply with the therapy (Gelmanova et al., 2006). 
The high number of poor treatment outcomes among the patients that did not comply with the 
therapy in this study could be the important indication for the effects treatment compliance 
has on outcomes that needed further exploration in different contexts (Gelmanova et al., 
2006). In addition, a study done in Iraq by Niazi and Al-Delaimi (2003) mentioned above 
also indicated the effects of treatment compliance on treatment outcomes. The study findings 
indicate that treatment compliance improved treatment cure rates. 
 
The findings from the USA based study by Jasmer et al. (2004) also mentioned above, 
indicate a high cure rate for patients treated under DOTS compared to patients treated 
through self-administered therapy (97.8% versus 88.6%, p < 0.002). The study further 
reported a decrease in TB related mortality in patients treated under DOTS from the start of 
their treatment up to the end of the therapy (0% vs. 5.5%, p = 0.002). A review by Volmink 
and Garner (2007), also mentioned above did not find any statistical difference in treatment 
completion between the range of DOTS and self-administered treatment as indicated by the 
cure rate which was similar for both outcomes. However these studies did not indicate how 
the patients complied with their treatments. 
 
Similarly, a Gambian study also mentioned above did not find statistical significant 
difference in treatment outcomes for patients treated through DOTS and those treated through 
self-administration. Cure rates, treatment completion rates, defaulter rate, treatment failures 
and death rates were closely related in these two treatment options (Afns & Ji, 2010). 
 
A Namibian study by Zvavamwe and Ehlers (2009) assessed the efficacy of the community-
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based DOTS programme compared to the standard hospital-based DOTS treatment in one of 
the Namibian regions. The findings indicate that those patients treated under community-
based DOTS had better cure rates compared to those treated under health facility-based 
DOTS. Community-based DOTS was also associated with high cure rates in a study by 
Volmink and Garner (2007), Jasmer et al. (2004) and Newell et al. (2006). However, both the 
studies and the review could not confidently infer that community-based DOTS improved 
cure rates, because the TB patients who did not select the community-based treatment option 
might have been different from those that opted for community-based DOTS. This could 
have been established through further analysis (Volmink & Garner, 1997; Zvavamwe & 
Ehlers, 2009).  
 
The above discussion indicates that non-compliance with TB treatment has adverse effects on 
treatment outcomes, while compliance improves cure rates. Higher cure rates were reported 
among patients treated under DOTS compared to self-administered treatment though some 
studies did not observe a significant difference between treatment outcomes. 
 
2.3.5 Factors affecting DOTS TB treatment compliance 
 
Several studies have been conducted to explore the factors affecting TB treatment compliance 
and identified the following factors as barriers and enhancers to TB treatment compliance: 
structural factors (financial burden, poverty and discrimination), patient factors (age, gender, 
motivation, knowledge, beliefs, attitudes, interpretations of illness, disease prognosis and 
medication side effects), social factors (community and family influence as well as social 
stigma), health care service factors (organization of treatment and care of TB patients) and 
other factors such as co-morbidities. 
 
2.3.5.1 Structural factors 
 
Many structural factors have been identified in previous research as factors influencing 
treatment compliance. An international systematic review by Munro et al. (2007) identified 
financial burdens as a structural factor mentioned in most of the reviewed studies influencing 
TB treatment compliance. In a study done in Gambia by Afns and Ji (2010), patients 
indicated that health facility-based daily medication increased their family expenditures 
 
 
 
 
 
 
17 
 
especially money spent on transport to and from the hospital. In other studies in sub-Saharan 
Africa and elsewhere, treatment interruption was associated with treatment costs either 
directly (paying for medications) or indirectly (hospital stays, transportation and change in a 
diet) (Barter et al., 2012; Greene, 2004; Lonnroth et al., 2009; Muture et al., 2011; Watkins & 
Plant, 2004). Studies have further highlighted that the difference between treatment options, 
work and indirect costs leads to expenses exceeding resources thus potentially pushing people 
into poverty (Greene, 2004; Munro et al., 2007). Studies further indicated that having TB had 
consequences for work and some patients hide their disease for fear of dismissal from their 
employment thus compromising their compliance with treatment (Barter et al., 2012; 
Edginton et al., 2002; Garner et al., 2007; Khan et al., 2000).  
 
A study done in Burkina Faso on barriers faced by patients and community members in 
accessing and adhering to TB treatment has independently identified geography and poverty 
as some of the factors associated with treatment interruption. Geography and poverty 
influence attendance of the health centre initially for diagnosis and repeatedly for daily 
DOTS as their health centres are centralised and DOTS require daily direct observation 
(Sanou et al., 2004). These findings applies to most sub-Saharan countries, Namibia included 
because even if the services are decentralised, there are still some hard to reach areas that 
makes services inaccessible to the unemployed and other economically disadvantaged and 
thus impacting on their compliance with care. 
 
Financial burden, work-related stigma, poverty and geography are some of the structural 
factors influencing TB treatment compliance identified in the above reviewed studies despite 
the difference in settings and difference in methodologies. 
 
2.3.5.2 Patient/personal factors 
 
There are a number of patient factors influencing TB treatment compliance. Treatment 
interruption was commonly attributed to lack of sufficient knowledge about TB, TB 
treatment, treatment duration and the consequences of non-compliance in most studies. In an 
international systematic review by Munro et al. (2007), non-compliance of TB treatment was 
attributed to insufficient knowledge about TB by TB patients. Findings from a Gambian 
study by Afns and Ji (2010) has also indicated that insufficient knowledge about TB among 
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TB patients contributed negatively to their treatment compliance. A descriptive cross-
sectional study carried out in Nepal by Newell et al. (2006) revealed that 61% of the non-
adherent patients indicated that they have stopped taking the treatment because they were 
feeling better and they attributed their treatment interruption to insufficient knowledge. These 
findings are consistent with the review by Munro et al. (2007) and with the study by Afns & 
Ji (2010). Newell et al. (2006) in a study conducted in Nepal further established that daily 
health education and knowledge of TB and its treatment were independently associated with 
adherence to treatment as confirmed by the multivariate analysis.  
 
A retrospective study done in Morocco by Dooley et al. (2011) on the risk factors for TB 
treatment failure indicate that male gender was one of the risk factors associated with 
treatment failure. In their study, male TB patients were more than two times likely to default 
from their treatment compared to their female counterpart (Dooley et al., 2011). This is an 
indication that males were less compliant compared to the females. While a separate study 
done in Tanzania by Van Den Boogaard et al. (2009) found that women, children, rural areas’ 
residents, newly diagnosed patients with smear-negative were most likely to be compliant 
with their TB treatment.  
 
Personal behavioural factors such as substance abuse and alcohol consumption were also 
found to influence treatment compliance in a range of studies in sub-Saharan Africa and 
beyond (Dooley et al., 2011; Khan et al., 2005; Munro et al., 2007; Walley et al., 2001). 
Alcohol and other substances as well as mental illness are believed to alter individuals’ 
behaviour, thus patients may forget to take their medications therefore leading to poor 
compliance.  
 
Studies further indicate that beliefs about treatment efficacy, denial and difficulty in 
accepting the diagnosis as well as personal interpretation of illness, are some of the personal 
factors affecting treatment compliance (Awofeso, 2008; Gebremariam et al., 2010; Munro et 
al., 2007).  
 
Some studies such as an international  review by Munro et al. (2007) as well as the Gambian 
study by Afns and Ji (2010) highlighted the impacts of treatment requirements on patient’s 
attitudes thus on adherence behaviour. Treatment requirements such as treatment duration 
that makes patients tired of taking the medications and fear of painful injections are some of 
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the factors that contribute to treatment interruption and non-compliance with the treatment 
(Afns & Ji, 2010; Awofeso, 2008; Munro et al., 2007). 
 
A study done in Kyrgyzstan by Awofeso (2008) identified side-effects to medications as one 
of the factors influencing treatment compliance among TB patients. The study found that 
more serious side-effects such as hepatitis, dyspepsia, exanthema and arthralgia were 
attributable to the interruption and termination of treatment of up to 23% of patients 
(Awofeso, 2008).In most studies (Awofeso, 2008; Kaona et al., 2004), medication side-
effects were mostly reported in the initial phase of treatment.  
 
As discussed above, studies in sub-Saharan Africa and elsewhere identified insufficient 
knowledge, gender, substance abuse and alcohol consumption, patients’ beliefs and attitudes 
and medication side effects as the patients’ factors likely to have an influence on treatment 
compliance despite the difference in settings and methods used 
 
2.3.5.3 Health service factors 
There are health service factors believed to either promote or hinder patients’ compliance 
with their TB treatment. A study done in Pakistan by Khan et al. (2005) indicated that for 
most patients, strategies used in administering treatment and care for TB patients through 
different types of DOTS plays a major role in treatment compliance. Patients feel that in most 
cases direct treatment observations are arranged to suit the treatment supporters schedule 
rather than that of the patients. This makes direct observation inconvenient and inflexible for 
patients thus potentially compromising compliance (Khan et al., 2005). In a Namibian study 
most of the participants (73%) preferred family members as their DOT supporter because 
they perceived them to be most convenient, acceptable and accessible (Zvavamwe & Ehlers, 
2009). 
 
Patient-centred approaches that allowed TB patients to choose the treatment option that was 
convenient and flexible to them was found to have improved the treatment outcomes for 
patients treated under both community and facility-based DOT. The approach further 
improved treatment success rates for patients who opted for community DOT rather than 
patients who chose facility-based DOT (Van Den Boogaard et al., 2009). 
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Studies identified the problems that are related to health-facility DOTS. Factors such as; 
availability and accessibility of health care facilities especially at the community level and 
availability of health workers were identified in some studies as factors influencing TB 
treatment compliance (Adane et al., 2013; Sanou et al., 2004). Other factors such as long 
waiting times, queues, poor TB medication availability lack of privacy and maltreatment by 
providers were identified in some qualitative studies both in sub-Saharan Africa and in other 
parts of the world as factors influencing health facility DOTS (Finlay et al., 2012; Greene, 
2004; Harper et al., 2003; Khan et al., 2000; Watkins & Plant, 2004). 
 
In some African studies and studies done elsewhere, health workers felt that daily DOTS 
increased their workload. Health workers attributed this workload to the treatment 
requirements where patients are seen and observed on a daily basis. For the proper 
implementation of the primary elements of DOTS, which is the monitoring of the progress of 
patients are also seen on regular basis  for  follow ups and sputum reviews (Afns & Ji, 2010; 
Podewils et al., 2013; Sanou et al., 2004; Van der Walt et al., 2007). 
 
 
2.3.5.4 Social factors 
 
Patients with TB do not only carry a burden of suffering from the disease, but their social life 
changes and are in most cases subjected to stigma and discrimination. In studies carried out in 
Kenya (Ayisi et al., 2011), Nigeria (Odusanya & Babafemi, 2004) and South Africa (Pronyk 
et al., 2001), discrimination against TB patient by family members, friends, co-workers and 
employers was strongly associated with treatment non-adherence and delay in seeking 
treatment. In a Gambian study, stigma was more prominent among females compared to their 
male counterpart (Afns & Ji, 2010). Stigma and discrimination does not only affect 
compliance and cause a delay in seeking treatment but further impact on TB control and it is 
more prevalent mostly in developing countries (Abioye et al., 2011; Cramm et al., 2010; 
Cramm et al., 2010; Kipp et al., 2011).  
 
In a cross-sectional study conducted in Nigeria, TB patients reported that stigma was 
common, forcing patients to hide their sickness, thus affecting their adherence to treatment 
(Abioye et al., 2011). Munro et al. (2007) in their systematic review identified peer influence, 
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lack of family and spouse support as some of the social factors that were strongly associated 
with non-compliance because of their strong influence on treatment taking behaviour. In a 
Gambian study by Afns and Ji (2010), full compliance with TB medication was described as 
a very challenging activity that requires patients to sacrifice important family responsibilities. 
A study done in South Africa by Cramm et al. (2010) on TB treatment initiation and 
adherence indicated that younger patients received more support from their family and 
friends compared to older TB patients and it helped them to comply more with their 
treatment. In a separate study by Govender (2009) on reasons why TB patients are not 
adhering to their treatment in South Africa, findings indicated that social support received 
from family and partners were significantly associated with adherence, while social support 
from friends was not associated with treatment adherence. 
 
Social factors influencing TB treatment compliance identified in this review were: stigma and 
discrimination as well as lack of social support despite the difference in study settings and 
study methods. 
 
2.3.5.5 Other factors 
 
The other factors associated with either compliance or non-compliance were co-morbid 
conditions such as cardiovascular diseases, diabetes and HIV. These conditions require 
patients to take additional medications in addition to TB treatment. Studies from sub-Saharan 
Africa and elsewhere indicated that patients may either comply because they want to get 
better, or they may decide not to comply because they feel worthless or they may become 
tired of taking a lot of medications (Bagchi et al., 2010; Bam et al., 2006; Brust et al., 2012; 
Daftary, 2012; Faurholt-Jepsen et al., 2012; Kaona et al., 2004; Munro et al., 2007). Non-
compliance with anti-TB treatment was considered high in the Ethiopian institutional cross-
sectional study by Adane et al. (2013) and being HIV positive was significantly associated 
with non-compliance. The authors attributed non-adherence to TB among HIV positive 
patients to the number of pills that TB/HIV co-infected patients have to take and the adverse 
effects of anti-TB medication that are more common in HIV infected patients. They further 
indicated that HIV/AIDS co-infected patients may be less motivated to take their medication. 
In a South African study, non-compliance with TB treatment among TB patient co-infected 
with HIV was attributed to poor integration between HIV and TB programmes (Atkins et al, 
2011). TB/HIV co-morbid was also strongly associated with non-compliance in a Ugandan 
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study by Amuha et al. (2009). 
  
This review identified co-morbidities such as cardiovascular diseases, diabetes and HIV as 
other factors influencing treatment compliance among TB patients. 
 
2.4 Gaps in knowledge 
 
Though the literature has provided a great amount of information on TB treatment 
compliance, most studies were either surveys or reviews and they could not indicate how 
compliance has been in all the phases of treatment and throughout the treatment duration. The 
studies have also not provided information on how compliance is distributed across a range of 
patients’ characteristics in different phases of treatment. Very few studies provided 
information on how compliance influences the treatment outcomes and the information was 
insufficient to draw conclusions on about the impacts of compliance on treatment outcomes. 
There are also very few studies that assessed compliance in Namibia. These gaps make this 
study imperative in providing new insights about TB treatment compliance and contribute to 
the available data in order to enable targeted interventions to be devised. 
 
Summary 
 
This literature review aimed at presenting the information available about TB treatment 
compliance in order to validate and justify the significance of the study. This was done 
through reviewing of the relevant literature on both compliance and adherence from reports 
and journals. The review mainly focused on the importance of treatment compliance, 
compliance with DOTS treatment, treatment compliance among different treatment 
strategies, treatment compliance and associated treatment outcomes in different treatment 
strategies and factors influencing DOTS treatment compliance. Correct and consistent 
compliance with prescribed TB treatment has been associated better treatment outcomes 
while non-compliance with TB treatment has been identified as a problem in many TB 
programmes and it is associated with increase in TB morbidity, poor treatment outcomes and 
an increase in health care costs. The WHO requires a TB treatment compliance of greater 
than 90% in facilitating cure and achieving treatment success. Compliance has been defined 
and measured differently in different settings, but most of the studies have adopted the WHO 
recommendation. Compliance with TB treatment has been reported to be low in most studies, 
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with the continuation phase of treatment identified as the most problematic phase when it 
comes to treatment compliance and one study recommending a cohort study to look into the 
rate of compliance. A WHO recommended compliance is adopted in this study to enable 
comparisons of the findings in different settings. Most studies that compared TB treatment 
among different strategies did not indicate how patients complied with their treatment and 
some did not indicate the type of DOT used, studies that did however have indicated that 
compliance was higher among community-based DOT. Non-compliance with TB treatment 
has adverse effects on treatment outcomes, while compliance improves cure rates. Higher 
cure rates were reported among patients treated under DOTS compared to self-administered 
treatment though some studies did not observe a significant difference between treatment 
outcomes. Financial burden, work-related stigma, poverty and geography are some of the 
structural factors influencing TB treatment compliance identified in the reviewed studies. 
Studies identified insufficient knowledge, gender, substance abuse and alcohol consumption, 
patients’ beliefs and attitudes and medication side effects as the patients’ factors influencing 
treatment compliance. Treatment strategies as well as availability and accessibility of health 
care services were identified by many studies as the health service factors influencing TB 
treatment compliance. Social factors influencing TB treatment compliance identified in this 
review were: stigma and discrimination as well as lack of social support. Co-morbidities were 
identified as other factors influencing treatment compliance among TB patients. In the efforts 
to fill the gaps identified in the literature, this study is trying to provide new insights about 
TB treatment compliance and contribute to the available data in order to enable targeted 
interventions to be devised.  
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CHAPTER 3: METHODS 
 
Introduction 
This Chapter focuses on the aims and objectives of the study, as well as the type of research 
and design used in this study. The study population, study setting, sampling procedure and 
the criteria used in the selection of the study participants will also be discussed. The Chapter 
will also describe the variables studied, methods used for extracting the data as well as the 
strategies used in the study to prevent bias and to ensure validity and reliability. Finally, the 
Chapter will discuss the statistical analyses conducted and the ethical considerations involved 
in the study.  
3.1 Aims and objectives 
3.1.1 Aim 
 
The aim of the study was to investigate TB treatment compliance and measure the 
relationship between patient characteristics as well as treatment outcomes and compliance 
among adult patients (age 15 and above) with PTB treated in Windhoek District during 1st 
January 2013 and 31st December 2013, in order to determine the effects of treatment 
compliance on treatment outcomes. 
 
3.1.2 Objectives 
 
The study objectives were: 
 To determine TB treatment compliance in these patients; 
 To compare compliance between initial and continuation phase of treatment;  
 To measure the association between patient characteristics and compliance;  
 To determine the prevalence of different treatment outcomes among these 
patients and 
 To measure the association between TB treatment compliance and treatment 
outcomes. 
 
 
 
 
 
 
 
25 
 
3.2  Study setting 
 
The study was conducted in Windhoek District, the largest district in Namibia and the only 
District in the Khomas region (one of the 13 regions in Namibia) where the capital city of 
Namibia is situated. Windhoek District is divided into Windhoek urban and rural of which 
the urban is the larger part of the District, while Windhoek rural is the portion of the district 
that consists of the farms at the outskirts of the city (NSA, 2011).  
 
According to the Namibian Statistics Agency (NSA) Namibia’s 2011 population and housing 
census (2014), Windhoek District has the total population of 342 141, of which almost equal 
numbers are women and men, with an annual growth rate of 3.1% in 2011. Ninety five 
percent of the population is living in urban areas. There are 89 438 households, with an 
average size of just under 4 persons per household. The age composition of the population 
suggests that those 15-59 years make up 69% of the total district’s population.  
 
The proportion of the people who are literate in Windhoek District is reported at 97%. About 
39% of the district’s population has completed primary education and 31% has completed 
secondary education. Seventy four percent of the population aged 15 years and above are 
economically active while 30% of the eligible population is unemployed (NSA, 2014). About 
56% of the district population lives below the poverty line and there is also high inequality as 
indicated by a Gini-coefficient of 0.5 (NSA, 2014). 
 
There are 12 government health facilities (seven Primary Health Care clinics, two Primary 
Health Care Centres, and two big hospitals of which one is an intermediate hospital and 
another a national referral hospital for specialized care). The District TB Unit is hosted in the 
intermediate hospital and it serves as a referral hospital for 3 other regions surrounding 
Khomas region in which Windhoek is based. All the clinics and health centres in the district 
offer basic health care services of which TB treatment is one, and it is offered free of charge, 
not only in Windhoek District but in the whole country. Daily, weekly, bi-weekly and 
monthly DOT is offered at 12 DOT points in the whole district which includes 9 health 
facilities and 3 community DOTS centres. There are also 6 private hospitals and several 
private consulting rooms that also offer TB treatment for fees and mostly cater for the middle 
and high income groups of the society (MoHSS, 2012).  
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3.3  Study type and design 
 
This was an observational analytic study, using a quantitative approach. A retrospective 
cohort design was used in this study in order to determine TB treatment compliance, factors 
influencing compliance and the effects compliance have on different treatment outcomes 
within this cohort. The study design is useful in examining the ‘possible relationship between 
exposures and outcomes” (Joubert & Ehrlich, 2012:79), the effect compliance has on 
treatment outcomes can also be determined. The cohort in this study was Pulmonary TB 
(PTB) patients started on TB treatment for the first time during the period of 1st January 2013 
to 31st December 2013.  
 
3.4  Population and sampling 
 
The targeted population were treatment cards of all adult PTB patients (15 years and above) 
treated on DOT in Windhoek District. While the study population comprised treatment cards 
of all new cases of adult PTB both sexes who were treated on DOT in Windhoek District 
during the study period. This study population was chosen so that by the time the study 
commenced patients would have completed 6 months of treatment and have available 
outcome measures. The study population size was 766 cases.  
 
Inclusion criteria 
 Treatment cards of all new adults PTB patients who received their TB treatment in the 
public health services via DOT in Windhoek District regardless of their HIV status 
were included in the study. 
 Treatment cards of all new adults PTB (PTB) patients started on TB treatment for the 
first time during the period of 1st January 2013 to 31st December 2013. 
 Treatment cards with some missing information were included in the study but were 
excluded from some analysis. 
Exclusion criteria 
 Treatment cards of patients with multi-drug resistance TB (MDR-TB), extensively 
drug-resistant TB (XDR-TB) or other forms of TB, complications such as TB 
meningitis, patients on alternative TB drugs that require different treatment durations 
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were excluded from the study because they require extended or varying duration of 
treatment. 
 Patients whose TB treatment cards were missing were excluded from the study. 
Using the District TB register, all patients that met the inclusion criteria were selected to be 
part of the study population. In this study, the study population and study sample are the same 
as there was no sampling done. In total 352 (46%) patients met the inclusion criteria and their 
treatment cards were all included in the study. The table below illustrates how the final cohort 
was selected to be part of the study and eventually analysed. 
 
Table 1: New PTB patients treated in Windhoek District between 1st January 2013 and 31st December 
2013. n=766 
Category of patients Number (N) Percentage (%) 
Other forms of TB such as Pleural Effusion 78 10 
TB complications such as TB meningitis 13 2 
Patients with Drug resistance TB 7 1 
Children under the age of 14 years with only PTB  207 27 
Missing TB treatment cards 109 14 
Patients that met the inclusion criteria 352 46 
Target population 766 100 
 
After operationalization of the inclusion and exclusion criteria as indicated above, 352 
patients’ treatment cards were included in the study.  
 
 
3.5  Data collection method 
 
Data collection method presents how the data was collected and the measures that were 
performed.  
 
3.5.1 Data collection  
 
Data was extracted by the researcher from the TB treatment cards using a data extraction tool 
(Appendix A). The data extraction tool was developed based on the data available on the 
standard Namibian TB treatment cards used for all TB patients on DOT in accordance with 
WHO standards. All patients that have met the inclusion criteria were selected from the TB 
register and their TB treatment cards were extracted for data collection.  
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Treatment cards of these patients were reviewed at the end of their TB treatment, to assess 
their compliance, socio-demographic and clinical factors affecting compliance, as well as 
their treatment outcome thus enabling the evaluation of the effects their compliance had on 
their treatment outcomes. Data collected from the treatment cards included: socio-
demographic data and clinical data that included the diagnostic classification, type of DOT 
and HIV status. Data on TB therapy and other medication the patient has taken as collected 
by the staff at the beginning of the treatment were also extracted. Compliance was measured 
in all phases of treatment by collecting data on daily doses taken/missed in the initial phase 
and in the continuation phase as well as the overall doses taken/missed. Overall compliance 
was calculated by adding compliance in the initial phase to the compliance in the 
continuation phase. Data on co-morbidities and side effects as well as patient education 
verification (at the beginning of the treatment, and the end of the initial phase and at 5 to 6 
months of treatment) and treatment outcome were also collected. Compliance was determined 
through the calculation of the total number of doses taken in comparison with the number of 
doses supposed to be taken.  
 
Retrospective data collection took place at the District TB unit’s outpatient department. At 
the beginning of the treatment and during other events occurring during the treatment such as 
co-morbidities, side-effects data was collected and recorded by doctors and nurses. While 
data on daily doses and patients’ knowledge through education verification at the end of each 
treatment phase is collected and recorded by nurses for those treated under health facility-
based DOT and by DOTS supporters for those treated under community-based DOT. TB 
treatment cards of all TB patients that were treated at different DOTS centres in the District 
are kept at the District TB unit. The researcher made use of a separate form for data 
collection (data extraction tool) for each patient’s treatment card and ensured that all patients’ 
treatment cards were kept safe at all times while in her possession. 
 
3.5.2 Measures  
 
The dependent variables were: treatment compliance (by looking at compliance in the initial 
phase, continuation phase and overall) and treatment outcomes (cured, treatment completed, 
defaulted and died). While the independent variables that were collected included socio-
demographic variables (age, gender, employment status and type of area) and clinical 
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variables (diagnostic classifications, type of DOT, HIV status, TB therapy doses taken (initial 
phase, continuation phase and overall); TB therapy doses missed (initial phase, continuation 
phase and overall), co-morbidities, other medications taken, alcohol consumption, medication 
side-effects and knowledge of TB through patient education verification).  
 
In determining the proportion of the doses taken out of the total doses the patient was 
supposed to take in 6 months; patient’s treatment cards were reviewed to count the actual 
number of doses taken as recorded in the treatment cards. In the initial phase of treatment 62 
doses were supposed to be taken while in the continuation phase 119 doses were supposed to 
be taken. A total of 181 doses were supposed to be taken by all patients fully treated over the 
6 months treatment period. 
 
Compliance was measured in the two phases and for overall compliance. Patients who took 
90% of the prescribed treatment per treatment phase were considered to have good 
compliance. Those patients that had taken between 40% and 90% of the prescribed doses 
were considered to have moderate compliance, while patients that have taken less than 40% 
of their treatment were considered to have poor compliance. Patients with good compliance 
were considered compliant while those with moderate and poor compliance were considered 
non-compliant. Overall compliance was calculated by adding compliance in the initial phase 
to the compliance in the continuation phase. This measurement could however not be 
performed for patients who died, defaulted and transferred out in the initial phase of 
treatment.  
 
Different treatment outcomes were obtained from the treatment cards as recorded at the end 
of 6 months of treatment or at the time treatment was ended.  
 
3.6  Data analysis 
 
Data collected was entered and analysed using Epi Info 7. Before data analysis, the data was 
cleaned and coded. Data cleaning and coding ran concurrently with data collection. The data 
extraction tools were checked for completeness and consistency before being entered into Epi 
Info. Raw data was coded into numerical and categorical variables to enable data analysis. 
Records in Epi Info were also checked and double checked for correctness and completeness 
against the data extraction tools. 
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Descriptive statistical analyses were used to summarize the data, measure central tendency 
and dispersion. Frequencies and proportions were used to summarize univariate categorical 
data. While for numerical data, means and standard deviations were used.  
 
Analytical statistics were used in bivariate analysis using chi-squared p-value ( ) to test for 
association between patients’ characteristics and compliance in different phases of treatment. 
These analyses were limited to those demographic and clinical variables that did not have a 
lot of missing data, to avoid the influence of missing data on the findings. Association was 
also tested between compliance in the various stages of treatment and treatment outcomes to 
determine the effects of compliance on treatment outcomes. In this analysis, age groups were 
collapsed into two groups namely; young adults were considered as patients aged 15 – 34 
years while older adults were considered as patients aged 35+ years. HIV status in this 
analysis was only done for those with known HIV status (positive and negative). Treatment 
outcomes were also collapsed into two categories, namely; treatment success (good treatment 
outcomes) were considered for those patients that are cured and those who completed their 
treatment, while poor treatment outcomes were considered for patients that defaulted, died, 
transfer out and those whose treatment failed before and after 5 months of treatment.  
 
A 5% confidence limits and 95% confidence interval was used in determining the 
significance level of the findings. To control variables for other associations, a multivariate 
regression using a logistic regression model was performed on variables that showed a 
statistically significant association in a bivariate analysis with a chi-squared p-value <0.05.  
 
3.7  Validity and reliability 
 
To ensure internal validity, selection bias was reduced by the use of inclusion and exclusion 
criteria. All the records from the study population that met the inclusion criteria were 
included in the study. Information bias was reduced through standardization of the data 
abstraction tool and ensuring that the information flow in the data extraction tool is the same 
as the information in the patients’ treatment cards. The data extraction tool was pre-tested on 
10 randomly selected records. This was done to ensure that the tool measures what it is 
intended to measure (Bonita et al., 2006). The tool was adjusted accordingly based on the 
results of the pre-test and the adjusted tool was used for data collection. Initially, the tool was 
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not made to capture missing data for most of the variables, but after the pre-test, the 
researcher had to adjust the tool for it to be able to capture the missing information which 
was notable in most of the records. A repeated measure on at least 5% of the data abstraction 
forms against the patients’ records was also done to ensure consistency and reliability of 
measurements (Bonita et al, 2006). External validity was ensured by having clear inclusion 
and exclusion criteria.  
 
3.8  Generalisability 
 
The results from this study will be generalized to all new adult PTB patients with no drug 
resistant strains and no other forms of TB on DOTS in Windhoek District and to new adult 
PTB patients with no drug resistant strains and no other forms of TB in similar settings in 
Namibia. This is because of similarities of the population and the likelihood of similar 
compliance and similar effects on treatment outcome. 
 
3.9 Ethical considerations 
 
Ethics permission was granted by University of the Western Cape Senate Research 
Committee (Appendix B). There were no individual consents for participants because there 
were no participants but rather reviewing of patients’ treatment cards. Written permission to 
conduct the study was sought from the Permanent Secretary (Appendix C), while permission 
to access patient’s records was sought from the Khomas Health Regional Director (Appendix 
D) and the Intermediate Hospital Katutura’s Medical Superintendent (Appendix E) 
respectively. 
Permission to conduct the research was obtained from the Ministry of Health and Social 
Services’ Permanent Secretary through the Ministry’s Research Unit (Appendix E), as well 
as from the Medical Superintendent of the Intermediate Hospital Katutura who is in charge of 
the District’s TB Unit (Appendix F).  
 
Anonymised data was extracted from the patients’ records by the researcher. Extraction was 
done at the TB outpatient department. Patients’ records are confidential documents that were 
safeguarded as required by the health ethics; therefore information obtained was kept fully 
confidential with no person other than the researcher allowed any access to the information.  
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Since this was a record review using existing data, there was no anticipated emotional harm 
involved in the study. The study findings will benefit the TB programme in devising targeted 
actions based on the study findings. The study findings will be presented to the District 
Management Team as well as to the District TB programme coordinators. The Ministry’s 
Research Unit and the District will be provided with the copy of results that will be kept for 
future reference. 
 
Summary 
 
The study aimed at investigating TB treatment compliance and its association on patient 
characteristics as well as treatment outcomes in order to determine the effects of compliance 
on treatment outcomes in Windhoek District. A quantitative observational analytic study 
using a retrospective cohort design was adopted. Treatment cards of new adult PTB patients 
treated under DOTS in the District during a specified period that met the inclusion criteria 
(352) were included in the study and there was no sampling done. Data was collected using 
data extraction tool in extracting the data from the patients TB treatment cards. Selection and 
information bias was eliminated by using clearly defined inclusion and exclusion criteria 
using a pre-tested standardized tool. Statistical analysis using descriptive and analytic 
statistics was done using Epi Info 7 to determine the prevalence of compliance, treatment 
outcomes and to measure the associations. Institutional Review Board approval and gate-
keeper approval was granted by relevant institutions. The next Chapter (Chapter four) will 
present the study findings. 
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CHAPTER 4: RESULTS 
 
Introduction 
 
This Chapter presents the findings of the study, starting with the description of the socio-
demographic and clinical characteristics of the study sample and findings about compliance 
in both phases of treatment and overall as well as treatment outcomes. The Chapter will 
further show the analysis of the variables associated with compliance, by looking at the chi-
squared p-values and multivariate logistic regression odds ratios (OR) to determine the 
associations. Finally, findings about the association between compliance and treatment 
outcomes will be presented in order to determine the effects of compliance on treatment 
outcomes.  
 
4.1 Characteristics of the study population 
 
4.1.1 Socio-demographic characteristics 
Table 2: Socio-demographic characteristics of new adult PTB patients treated in Windhoek District 
between 1st January and 31st December 2013 stratified by sex at baseline. n=352  
Socio-demographic characteristics Sex Total N (%) 
 Female n (%) Male n (%)  
Age groups    
15 – 24 27 (20.5) 32 (14.6) 59 (16.8) 
25 – 34 49 (37.0) 70 (31.8) 119 (33.8) 
35 – 44 28 (21.2) 66 (30.0) 94 (26.7) 
45 – 54 19 (14.4) 37 (16.8) 56 (15.9) 
55 + 9 (6.9) 15 (6.8) 24 (6.8) 
 132 (100) 220 (100) 352 (100) 
Age range (years)  15 - 85 15 - 85 15 - 85 
Mean age (years), SD 35.1 ± 12.6 36.9 ± 11.3 36.2 ± 11.8 
Employment status    
Employed 4 (3.0) 10 (4.6) 14 (4.0) 
Unemployed 16 (12.1) 15 (6.8) 31 (8.8) 
Not recorded 112 (84.9) 195 (88.6) 307 (87.2) 
 132 (100) 220 (100) 352 (100) 
Type of area    
Rural 12 (9.1) 12 (5.5) 24 (6.8) 
Urban 120 (90.9) 208 (94.5) 328 (93.2) 
 132 (100) 220 (100) 352 (100) 
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 The largest proportion of the study cohort were adults aged 25 to 34 years 119 (38.8%) that 
comprised more females 49 (37%) than males 70 (31.8%).While the smaller portion of this 
population 24 (6.8%) came from older adults aged 55 years and above. The majority of the 
records 307 (87%) did not indicate the employment status of the patients and more males 195 
(88.6%) did not have their employment status recorded. Employment could therefore not be 
included in further analysis due to the missing data. Ninety-three percent (328) of the patients 
came from urban areas, with a larger proportion of males 208 (94.5%) living in urban areas. 
 
4.1.2 Clinical characteristics 
 
Clinical information about the study population is presented in two tables. Table 3 presents 
the clinical information that was collected at the beginning of the treatment, referred to as the 
baseline, while Table 4 presents the clinical information specifically co-morbidities that was 
collected throughout the treatment duration (pre-treatment, at the end of the initial phase and 
at the end of the continuation phase).  
 
Table 3:  Clinical characteristics of new adult PTB patients treated in Windhoek District between 1st 
January 2013 and 31st December 2013 stratified by sex at the baseline. n=352  
Patients’ clinical information Sex Total n (%) 
 Female n (%) Male n (%)  
Diagnostic classification    
 Pulmonary TB smear positive 105 (79.5) 163 (74.1) 268 (76.1) 
 Pulmonary TB smear negative 20 (15.2) 38 (17.3) 58 (16.5) 
 Pulmonary TB no smear 7 (5.3) 19 (8.6) 26 (7.4) 
 132 (100) 220 (100) 352 (100) 
Type of DOT     
Close relative  6 (4.5) 2 (0.9) 8 (2.3) 
Guardian-relative, neighbour 3 (2.3) 1 (0.5) 4 (1.1) 
Community Health Worker 5 (3.8) 12 (5.5) 17 (4.8) 
Community-based DOT 14(10.6) 15 (6.9) 29 (8.2) 
Health Facility-based DOT 118 (89.4) 205 (93.1) 323 (91.8) 
 132 (100) 220 (100) 352 (100) 
HIV status     
Negative 68 (51.5) 100 (45.4) 168 (47.7) 
Positive 60 (45.5) 104 (47.3) 164 (46.6) 
Unknown 4 (3.0) 16 (7.3) 20 (5.7) 
 132 (100) 220 (100) 352 (100) 
 
The majority of the patients 268 (76.1%) were treated for Pulmonary TB smear positive, 
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which was reported more among females 105 (79.5%) (Table 3). Ninety two percent (323) of 
the patients were treated under health facility-based DOT and the majority of males.  
 
According to the records, 168 (48%) of the patients were HIV negative, while 164 (46.6%) 
were HIV positive. The prevalence of HIV among new adult patients treated in Windhoek 
District between 1st January 2013 and 31st December 2013 was 46.6%. 
 
Table 4 presents how co-morbidities were distributed across the phases of treatment stratified 
by sex. There was no much difference in co-morbidities recorded at the commencement of 
TB treatment 148 (42.1%) and co-morbidities recorded at the end of each phase of treatment, 
with 143 (45.6%) and 132 (45%) at the end of the initial and continuation phase of treatment 
respectively. HIV was the most frequently recorded co-morbidity in all phases of treatment 
with 142 (96%) at the beginning of the treatment and 126 (96.9%) at the end of the 
continuation phase of treatment. 
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Table 4: Clinical information on co-morbidities of the 352 new adult PTB patients treated in Windhoek District between 1st January 2013 and 31st December 
2013 in the phases of treatment stratified by sex. n=352 
Patients’ clinical information Sex Total N (%) 
 Female n (%) Male n (%)  
 Pre-treatment Initial phase Continuation 
phase 
Pre-treatment Initial phase Continuation 
phase 
Pre-
treatment 
Initial phase Continuation 
phase 
Co-morbidities recorded          
Yes 54 (40.9) 49 (42.6) 44 (41.5) 94 (42.7) 94 (47.2) 86 (46.2) 148 (42.0) 143 (45.5) 130 (44.5) 
No 78 (59.1) 66 (57.4) 62 (58.5) 126 (57.3) 105 (52.8) 100 (58.8) 204 (58.00) 171 (54.5) 162 (55.4) 
 132 (100) 115 (100) 106 (100) 220 (100) 199 (100) 186 (100) 352 (100) 314 (100) 292 (100) 
Co-morbidities conditions           
HIV 50 (92.6) 48 (98.0) 44 (100) 93 (98.9) 93 (98.9) 82 (95.4) 143 (96.6) 141 (98.6) 126 (96.9) 
Others 4 (6.4) 1 (2.0) - 1 (1.1) 1 (1.1) 4 (4.6) 2 (3.4) 2 (1.4) 4 (3.1) 
 54 (100) 49 (100) 44 (100) 94 (100) 94 (98.9) 86 (100) 148 (100) 143 (100) 130 ( 100) 
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4.2 Treatment compliance and treatment outcomes 
 
Table 5: Treatment compliance and treatment outcomes of new adult PTB patients treated in 
Windhoek District between 1st January 2013 and 31st December 2013 by sex. n=352 
Compliance and Treatment outcomes Sex Total 
Compliance Female  Male   
Mean Anti- TB dosages taken, SD Mean ± SD Mean ± SD Mean ± SD 
Initial phase  61.7 ± 14.6 63.2 ± 15.0 62.6 ± 14.8 
Continuation phase 111.3 ± 27.6 109.9 ± 31.1 110.5 ± 29.9 
Overall 173 ± 42.2 173.1 ± 46.1 173.1 ± 44.7 
Compliance  n (%) n (%) N (%) 
Initial phase     
Good compliance  128(97.0) 214(97.2) 342 (97.2) 
Compliant 128(97.0) 214(97.2) 342 (97.2) 
Moderate compliance 3(2.2) 4 (1.9) 7 (2.0) 
Poor compliance 1(0.8) 2 (0.9) 3 (0.8) 
Non-compliant 4 (3.0) 6 (2.8) 10 (2.8) 
 132(100) 220 (100) 352 (100) 
Continuation phase*    
Good compliance 101 (87.8) 179 (88.2) 280 (88.0) 
Compliant 101 (87.8) 179 (88.2) 280 (88.0) 
Moderate compliance 11(9.6) 13 (6.4) 24 (7.6) 
Poor compliance 3(2.6) 11 (5.4) 14 (4.4) 
Non-compliant 14 (12.2) 24 (11.8) 38 (12.00) 
 115 (100) 203 (100) 318 (100) 
Overall*    
Good compliance 102 (88.7) 181 (89.2) 283 (89.0) 
Compliant 102 (88.7) 181 (89.2) 283 (89.0) 
Moderate compliance 10 (8.7) 13 (6.4) 23 (7.2) 
Poor compliance 3 (2.6) 9 (4.4) 12 (3.8) 
Non-compliant 13 (11.3) 22 (10.8) 35 (11.0) 
 115 (100) 203 (100) 318 (100) 
Treatment outcomes    
Cured 73 (63.5) 118 (56.5) 191 (58.9) 
Treatment completed 29 (25.2) 59 (28.2) 88 (27.2) 
Treatment success 102 (88.7) 177 (84.7) 279 (86.1) 
Defaulted 4 (3.5) 14 (6.7) 18 (5.6) 
Died 8 (7.0) 13 (6.2) 21 (6.5) 
Treatment failure 1 (0.8) 5 (2.4) 6 (1.8) 
Poor treatment outcomes 13 (11.3) 32 (15.3) 45 (13.9) 
 115(100) 209 (100) 324 (100) 
*Compliance in the continuation phase and overall compliance was not measured for the 34 patient that either 
died, defaulted or those that were transferred out in the initial phase of treatment, therefore it was only measured 
in 318 records. 
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Table 5 presents information on compliance and treatment outcomes of adult PTB patients 
treated via DOTS in Windhoek District stratified by sex.  
 
Compliance in the initial phase of treatment was measured in all 352 patients’ records. While 
in the continuation phase and overall, compliance was only measured in 318 records 
excluding the records of patients that either died, defaulted or those that were transferred out 
in the initial phase of treatment.  
 
In the initial phase, 342 (97.2%) patients were compliant almost equally distributed between 
males 214 (97.2%) and females 128 (97%). In the continuation phase, 280 (88%) patients 
were compliant, with compliance recorded slightly more in males 179 (88.2%) than females 
101 (87.8%). Whereas for overall compliance, 283 (89%) patients were compliant with males 
181 (89.2%) showing slightly better compliance than females 102 (88.7%).  
 
The initial phase displayed high compliance while compliance in the continuation phase was 
similar to overall compliance (88.7%).  
 
As indicated in Table 5, treatment outcomes were measured only in 324 patients, excluding 
those patients who are transferred out. This gives the prevalence of different treatment 
outcomes among adult PTB patients treated via DOTS in Windhoek District over a specified 
period. . Treatment success in all 324 patients was 86.1% over six months as indicated by 191 
(58.9%) cure and 88 (27.2%) treatment completed. There was no significant difference in 
treatment success between males and females.  
 
Moreover, 18 patients (5.6%) defaulted to give a defaulter rate of 51 per 1000 TB cases per 6 
months. Males 14 (6.7%) defaulted more compared to 4 (3.5%) females. Six and half percent 
(21) of the patients died, this outcome was observed more among females 8 (7%). Treatment 
failure occurred in about two percent (6) of the patients and it was recorded more among 
males 5 (2.4%) than among females with less than one percent. Poor treatment outcomes as 
represented by those patients that defaulted 18 (5.6%), died 21 (6.5%) and whose treatment 
failed 6 (1.8%) was reported at 45 (13.9%).  
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4.3 Association between a range of patients’ characteristics and compliance in 
the initial, continuation phase and overall treatment compliance 
 
Association between socio-demographic and clinical characteristics and compliance of the 
352 new adult PTB patients was based on the observed percentages and the chi-squared ( ) 
p-values. Those variables that showed an association of p-value=0.05 and below were 
analysed further using a multivariate regression to control for other associations.  
4.3.1 Association between patients’ characteristics and compliance in the 
initial phase of treatment 
 
Table 6: Association between patients’ characteristics and compliance of new adult PTB patients 
treated in Windhoek District between 1st January 2013 and 31st December 2013 in the initial phase of 
treatment. n=352 
Patients’ characteristics Compliant n (%) Non-compliant n 
(%) 
 P-value 
Socio-demographic information     
Age category     
Young adults (15 – 34) 172 (96.6) 6 (3.4) 0.37 0.54 
Older adults (35+) 170 (97.7)  4 (2.3)   
Sex     
Male 214 (97.3) 6 (2.7) 0.03 0.86 
Female 128 (97.0)   4 (3.0)   
Type of area     
Rural 22 (91.7) 2 (8.3) 2.81 0.09 
Urban 320 (97.6) 8 (2.4)   
Clinical information     
Diagnostic classification     
Pulmonary TB smear 
positive 
261 (97.4) 7 (2.6) 0.21 0.64 
Other PTB (smear 
negative and no smear) 
81 (96.4)  3 (3.6)   
Type of DOT     
Community-based DOT 28 (96.6)   1 (3.4) 0.04 0.83 
Health Facility-based DOT 314 (97.2) 9 (2.8)   
HIV status     
Negative 164 (97.6) 4 (2.4) 0.14 0.70 
Positive 159 (97.0) 5 (3.0)   
*statistically significant association 
  
There were no statistically significant associations observed between patients’ socio-
demographic and clinical characteristics and compliance in the initial phase of treatment. 
However, it is should be noted that the results of type of area ( =2.81, P value=0.09) were 
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approaching the significance level in this phase with majority of patients from urban areas 
complying with 97.6% compared with those from rural areas 91.7%.   
 
4.3.2 Association between patients’ characteristics and compliance in the 
continuation phase of treatment  
 
Table 7 presents association between patients’ socio-demographic and clinical characteristics 
and compliance of the 318 new adult PTB patients.  
 
Table 7: Association between patients’ characteristics and compliance of new adult PTB patients 
treated in Windhoek District between 1st January 2013 and 31st December 2013 in the continuation 
phase of treatment. n=318  
Patients’ characteristics Compliant n 
(%) 
Non-compliant 
n (%) 
 P-value Multivariate logistic 
regression 
Socio-demographic 
information 
    Odds 
ratio 
(95% CI) 
P-value 
Age category       
Young adults (15 – 
44) 
136 (84.5) 25 (15.5) 3.97 0.05* 4.13 (1.72 
– 9.90) 
<0.01* 
Older adults (35+) 144 (91.7) 13 (8.3)     
Sex       
Male 179 (88.2) 24 (11.8) 0.01 0.92   
Female 101 (86.8)  14 (12.2)     
Type of area       
Rural 15 (62.5) 9 (37.5) 16.11 <0.01* 0.02 (0.00 
- 0.13) 
0.05* 
Urban 265 (90.1)  29 (9.9)     
Clinical information       
Diagnostic classification       
Pulmonary TB 
smear positive 
214 (88.4) 28 (11.6) 0.14 0.70   
Other PTB (smear 
negative and no 
smear) 
66 (86.8) 10 (13.2)     
Type of DOT       
Community-based 
DOT 
22 (81.5) 5 (18.5) 1.21 0.27   
Health Facility-
based DOT 
258 (88.7) 33 (11.3)     
HIV status       
Negative 137 (87.8) 19 (12.2) 0.01 0.92   
Positive 127 (88.2) 17 (11.8)     
*statistically significant association 
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In the continuation phase of treatment and among age categories, very high compliance was 
observed among older adults (patients aged 45+years) with 91.7%. These results ( =3.97, P 
value=0.05) indicate a marginal statistically significant association.   
 
As in the initial phase of treatment, the majority of patients from urban areas complied 
(90.1%), whereas patients from rural areas compliance were lower with 62.5%. The results 
( =16.11, p-value=<0.01) indicate a statistically significant association. 
 
In the multivariate regression using a logistic regression model, the only variables that 
showed a significant association in this phase were age (OR=4.3 95% CI (1.72 – 9.90), p-
value=<0.01) and type of area (OR=0.02 95% CI (0.00 – 0.13), p-value=0.05). The odds of 
compliance are 4.13 among older adults (patients aged 45+years) in comparison with young 
adults (patients aged 15 – 34 years). While the odds of compliance is 0.02 for patients from 
rural areas compared to patients from urban areas.  
 
In the continuation phase of treatment, age and type of area were associated with compliance 
with older adults (patients aged 35+years) more likely to comply than young adults (patients 
aged 15 – 34 years) and patients from rural areas less likely to comply with their treatment 
than those from other communities. 
 
4.3.3 Association between patients’ characteristics and overall compliance 
 
Table 8 presents association between the socio-demographic and clinical characteristics of 
the 318 new adult PTB patients and overall compliance based on the observed percentages 
and chi-squared p-values and multivariate logistic regression odds ratio and p-values. 
 
Among age categories, overall compliance was similar to the initial and different to that in 
the continuation phase of treatment. High overall compliance 92.4% were observed in older 
adults (patients aged 45+ years). The results ( =3.58, P value=0.04) show a  statistically 
significant association between age and overall treatment compliance as in the continuation 
phase of treatment, with older adult patients more likely to comply with their treatments than 
young adults. 
 
 As in the initial and continuation phase of treatment, a large number of patients from urban 
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areas complied (91.2%), whereas patients from rural areas’ compliance was relatively low 
with 62.5%, like in the continuation phase. The results ( =18.60, P value=<0.01) indicate a 
statistically significant association between type of area and overall treatment compliance.  
 
Table 8:  Association between patients’ characteristics and overall compliance of new adult PTB 
patients treated in Windhoek District between 1st January 2013 and 31st December 2013. n=318 
Patients’ characteristics Compliant n 
(%) 
Non-compliant 
n (%) 
 P-value Multivariate Logistic 
regression 
Socio-demographic 
information 
    Odds ratio 
(95% CI) 
P-value 
Age category       
Young adults (15 – 
34) 
138 (85.7) 23 (14.3) 3.58 0.04* 1.03 (0.18 
– 7.83) 
0.08 
Older adults (35+) 145 (92.4) 12 (7.6)     
Sex       
Male 181 (89.2) 22 (10.8) 0.02 0.89   
Female 102 (88.7) 13 (11.3)     
Type of area       
Rural 15 (62.5) 6 (37.5) 18.60 <0.01* 0.03 (0.00 
– 0.91) 
0.04* 
Urban 268 (91.2)  26 (8.8)     
Clinical information       
Diagnostic classification       
Pulmonary TB 
smear positive 
217 (89.7) 25 (10.3) 0.47   0.49   
Other PTB (smear 
negative and no 
smear) 
66 (86.8) 10 (13.2)     
Type of DOT       
Community-based 
DOT 
22 (81.5) 5 (18.5) 1.70 0.19   
Health Facility-
based DOT 
261 (89.7) 30 (10.3)     
HIV status       
Negative 139 (89.1) 17 (10.9) 0.00 0.95   
Positive 128 (88.9) 16 (11.1)     
*statistically significant association 
 
As in the continuation phase of treatment, those variables that showed a statistically 
significant association including age and the type of area were analysed further in a 
multivariate regression using a logistic regression model to control for other factors. The 
results show that in the model age is not associated with overall compliance (OR=1.03 95% 
CI (0.18 – 7.83), p-value=0.08) although the results were approaching significance indicating 
that older adult patients have higher compliance than young adult patients. The type of area 
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(OR=0.03 95% CI (0.00 – 0.91), p-value=0.04) remains statistically significant, with the odds 
of compliance 0.03 for patients from rural areas compared to patients from urban areas.  
 
4.4 Association between compliance and treatment outcomes 
 
Table 9 presents the association between compliance in each phase of treatment, as well as on 
overall compliance, and treatment outcomes to assess the relationship between treatment 
compliance and treatment outcomes. These associations are based on the observed 
percentages, bivariate chi-squared p-values.  
 
Table 9: Association between compliance in all phases of treatment and treatment outcomes of new 
adult PTB patients treated in Windhoek District between 1st January 2013 and 31st December 2013. 
n=352   
Treatment 
compliance  
 Treatment 
success 
 Poor 
treatment 
outcomes 
   P-value  
Initial phase n=324           
Compliant  278 (88.5)  36 (11.5)  49.98  <0.01*  
Non-compliant   1 (10.0)   9 (90.0)      
 
Continuation phase 
n=313 
         
Compliant  263 (95.6)  12 ( 4.4)  98.81  <0.01*  
Non-compliant   16 (42.1)  22 (57.9)      
 
Overall compliance 
n=313 
         
Compliant   266 (95.7)   12 (4.3)  110.02  <0.01*  
Non-compliant   13 (37.1)   22 (62.9)      
*statistically significant association 
 
In the initial phase poor treatment outcomes appeared higher among those patients who did 
not comply with their treatment 9 (90%) compared to only 36 (11.50%) poor outcomes 
observed among those patients who were compliant with their treatments. Treatment success 
was 278 (88.50%) among patients that complied with their treatment and much lower 1 
(10%) among those patients that did not comply with their treatment. The results ( =49.98, 
P value=<0.01) show a statistically significant association between treatment compliance in 
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the initial phase of treatment and treatment outcomes. This clearly indicates that those 
patients who are non-compliant in this phase of treatment have poorer treatment outcomes 
while those with good compliance have good treatment success. 
 
In the continuation phase, treatment success amongst compliant patients seems to increase 
(95.6%) as does treatment success amongst those non-compliant 16 (42.1%). The results 
( =98.81, P value=<0.01) still show a statistically significant association between treatment 
compliance in the continuation phase of treatment and treatment outcomes. The chi-squared 
test result further indicates a strong association between treatment compliance in the 
continuation phase and treatment outcomes.  
 
Overall, treatment success appeared higher among those patients that complied with their 
treatment 266 (95.7%) compared to those patients who were less compliant with their 
treatment 13 (37.1%). Poor treatment outcomes seemed higher among the patients that 
complied less with their treatment 22 (62.9%). The results ( =110.02, P value=<0.01) show 
a statistically significant association between overall treatment compliance and treatment 
outcomes. The chi-squared test result further indicates strong association between treatment 
compliance throughout the initial and continuation phase of treatment and treatment 
outcomes.  
 
Summary 
 
The study findings are based on the records of 352 new adult PTB patients treatment via 
DOTS in Windhoek District over a specified period. The analyses comprised 63% males and 
37% females aged 15 to 82 years with a mean age of 36.2 years and a standard deviation of 
11.8 years. The largest proportion of the study population were adults age 25 – 34 years; from 
urban areas; on health facility-based DOT; with PTB smear positive and HIV negative 
patients. HIV prevalence is recorded at 46.6%. Treatment success among the cohort was 
86.1%. In the initial phase of treatment there were no factors that appeared to be associated 
with compliance. In the continuation phase of treatment age and type of area are associated 
with compliance with older adult patients aged 45+ years more likely to comply and patients 
from rural areas less likely to comply with their treatment. Overall, type of area is associated 
with treatment compliance while the relationship with age is no longer observed in the 
regression model. The results further indicate that poor treatment outcomes are associated 
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with non-compliance while treatment success is associated with compliance.
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CHAPTER 5: DISCUSSION 
 
Introduction 
 
This Chapter discusses the findings of the study in line with the study objectives and in 
relation to the literature. Compliance with TB treatment remains important to the success of 
TB control programmes (Adane et al., 2013; Afns & Ji, 2010; Naidoo et al., 2013). This study 
contributes to the knowledge of TB treatment compliance, by revealing some important 
information on compliance, factors affecting compliance and the effects of TB treatment 
compliance on treatment outcomes in new adult PTB patients treated on DOTS in Windhoek 
District in Namibia. In keeping with the study objectives, the discussion will look at overall 
compliance as well as compliance in the two key phases of treatment. The discussion will 
further look at the factors associated with compliance as well as the association between 
treatment compliance and treatment outcomes in order to determine the effects of treatment 
compliance on treatment outcomes as well as the limitations of the study. 
 
The key findings of the study show that overall treatment compliance was 89% with initial 
phase and continuation phase, 97.2% and 88% respectively. Treatment success among the 
cohort was 86.1%.  
 
There were no factors associated with compliance in the initial phase of treatment, while in 
the continuation phase of treatment age and type of area were statistically significantly 
associated with compliance. Older adult patients aged 45+ years were more likely to comply 
with their treatment than young adult patients aged 15 – 34 years, while patients from rural 
areas were less likely to comply with their treatment compared to patients from urban areas. 
Overall, type of area is statistically significantly associated with treatment compliance, with 
patients from rural areas less likely to comply with their treatment compared to patients from 
rural areas. The results further suggest that treatment compliance seems to have an effect on 
treatment outcomes. Compliance is statistically significantly associated with treatment 
success.  
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5.1 Treatment compliance  
 
The study shows overall compliance as well as compliance in the initial and continuation 
phase of treatment in Windhoek District among adult PTB patients treated under DOTS. The 
study indicated high compliance in the initial phase of treatment (97.2%). Compliance is 
higher than the WHO recommended 90% compliance as indicated by the literature (Adane et 
al., 2013; Awofeso, 2008; Takarinda et al., 2012). The continuation phase and overall 
compliance were higher than expected, 88.1% and 89% respectively but below the WHO’s 
90% recommended  compliance as indicated by the literature (Adane et al., 2013; Awofeso, 
2008; Takarinda et al., 2012). This indicates that patients were more compliant with their 
treatments in the initial phase of treatment and became less compliant/ non-compliant in the 
continuation phase of treatment, which has affected their overall compliance. High 
compliance in the initial phase of treatment which is above the WHO recommended 
compliance is a good indication for TB treatment compliance in Windhoek District. It 
indicates that patients in Windhoek District are capable of complying with their treatment 
throughout their treatment duration if support is given to both the patients and the treatment 
supporters. This will enable the District to achieve and surpass the WHO recommended 
treatment success. 
 
In this study non-compliance varies by the phase of treatment from about 12% in the 
continuation phase to less than 3% in the initial phase. A review by Castelnuovo (2010) on 
compliance with anti-TB treatment in sub-Saharan Africa non-compliance from ranged from 
11.3% to 29.6%. Another study done in Uganda reported the prevalence of non-compliance 
with TB at 25% and a study from Ethiopia found non-compliance of 10% to 13.6% (Adane et 
al., 2013; Amuha et al., 2009). However, it should be noted that in Castelnuovo's (2010) 
review compliance in the studies was determined through defaulters, while this study 
assessed compliance based on WHO’s recommended 90% use of prescribed medication. The 
Ethiopian and Ugandan studies assessed compliance over four days and five days preceding 
their surveys respectively, which is also different from the way compliance was measured in 
this study.  
 
Looking at non-compliance identified in this study that varies from 2.8% to 11.9% in 
comparison to non-compliance findings from other studies, non-compliance in this study is 
relatively lower. This could be due to the different measures used in other studies. Unlike 
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other studies previously conducted, this study assessed overall compliance over the whole 
treatment duration which is 6 months and compliance was also assessed in both phases of 
treatment separately. The method used in this study to measure compliance was useful in 
determining how non-compliance was occurring throughout the treatment duration and 
should enable recommendations for targeted interventions to be devised. 
 
In many TB programmes, treatment compliance has been associated with high TB cure rates 
and reduction in the emergence of drug resistance (Adane et al., 2013; Afns & Ji, 2010; 
Naidoo et al., 2013). Therefore, consistent compliance in TB patients receiving treatment 
through DOTS is required throughout the treatment period for the achievement of good 
treatment outcomes which is key to achieving high cure rates (Naidoo et al., 2013). This 
study found that compliance has not been consistent throughout the treatment duration and 
the continuation phase of treatment was found to be the most problematic phase when it 
comes to treatment compliance. The highest non-compliance reported in this study of about 
12% was reported in the continuation phase of treatment. These findings concur with the 
literature from sub-Saharan Africa that found the continuation phase to be the most 
problematic phase when it comes to compliance with TB treatment (Afns & Ji, 2010; Amuha 
et al., 2009; Castelnuovo, 2010).  
 
Non-compliance with TB treatment in the continuation phase of treatment could be due to a 
number of factors. Studies attributed treatment interruption mostly to lack of sufficient 
knowledge about TB, TB treatment, treatment duration and the consequences of non-
compliance (Munro et al., 2007; Afns & Ji, 2010). Studies further attribute treatment 
interruptions to the disappearance of symptoms that occurs mostly in the continuation phase 
of treatment (Munro et al., 2007; Newell et al., 2006). Since most patients in this study were 
treated under health facility based DOT, non-compliance in the continuation phase could also 
be due to financial burdens as Munro et al. (2007) and Afns and Ji (2010) have indicated that 
health facility-based daily medication have the potential of increasing family expenditures 
especially money spent on transport to and from the hospital. However, this study could not 
provide conclusive evidence on the factors contributing to non-compliance with TB treatment 
in the continuation phase of treatment but rather recommends that future studies explore this. 
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5.2 Factors influencing TB treatment compliance 
 
Compliance with TB treatment remains beneficial in TB control programmes especially 
programmes that fall under the DOTS strategy. In many TB programmes, treatment 
compliance has been associated with high TB cure rates and reduction in the emergence of 
drug resistance (Adane et al., 2013; Afns & Ji, 2010; Naidoo et al., 2013). Treatment 
compliance can only be achieved if factors influencing compliance are known. Some of the 
most cited factors affecting TB treatment compliance in sub-Saharan Africa and beyond 
include financial burdens (Munro et al. 2007), treatment costs (Barter et al., 2012; Greene, 
2004; Lonnroth et al., 2009; Muture et al., 2011; Watkins & Plant, 2004), geographic area 
(Sanou et al., 2004), insufficient knowledge about TB among TB patients (Munro et al., 
2007; Newell et al., 2006), gender (Dooley et al., 2011; Van Den Boorgard et al., 2009).  
 
Other factors such as personal behaviours including substance abuse and alcohol 
consumption (Dooley et al., 2011; Khan et al., 2005; Munro et al., 2007; Walley et al., 2001), 
personal interpretation of illness and cure (Awofeso, 2008; Gebremariam et al., 2010; Munro 
et al., 2007), medication side-effects (Awofeso, 2008; Kaona et al., 2004) were also cited. 
Social factors, health service factors and other factors such as co-morbidities were also 
identified as factors influencing TB treatment compliance (Barter et al., 2012; Greene, 2004; 
Lonnroth et al., 2009; Munro et al., 2007; Muture et al., 2011; Watkins & Plant, 2004). This 
study assessed some of these factors in the initial phase and continuation phase of treatment 
as well as overall. This was to assess how these factors were occurring in the treatment 
duration and to see if there was an association with compliance.  
 
In this study, the findings indicate that there were no factors associated with compliance in 
the initial phase of treatment. While in the continuation phase age and type of area were 
statistically associated with compliance, with patients older adult patients aged 45+ years 
more likely to comply with their treatment compared to patients from other ages. In the 
continuation phase older adult patients aged 45+ years’ compliance could be due to a number 
of factors. This age category represents older people, whose level of responsibility might be 
higher compared to that of younger adults. Most of these adults are at the helm of their 
employment, therefore they are likely to take all the responsibilities; those related to their 
employment and those related to their health. Being employed also means that their 
accessibility to care is better than that of the younger adults. In the absence of the literature 
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confirming that the above mentioned reasons are the actual reasons why the older adult 
patients are complying, this study is not providing conclusions on why that age category is 
more likely to be compliant than all the younger adults. But rather identifying the gaps that 
need to be filled by future research.  
 
 The findings about the type of area being associated with compliance are similar to the 
findings of a study done in Burkina Faso (Sanou et al., 2004), who indicated that geography 
has got an influence on health centre attendance for daily DOTS. However, in Sanou et al.'s 
(2004) study, patients from rural areas were more compliant with their treatment compared to 
patients from urban areas. This was because most patients in their study were treated via CB 
DOTS because it was more accessible to them. In this study, many patients were treated 
through health facility-based DOT, because there were more health facility-based DOT in the 
district than CB DOT (MoHSS, 2013).  
 
5.3 Treatment outcomes 
 
There was not much difference in treatment outcomes reported in this study and the national 
treatment outcomes reported by the MoHSS (2013).This study has reported a cure and 
treatment completed of 58.9% and 27.2% respectively. This translates into treatment success 
of 86.1% over six months, which is higher than expected because it is slightly higher than the 
national treatment success of 83% and the treatment success of 85% reported in a study done 
in Nepal (MoHSS, 2013; Newell et al., 2006). This study’s treatment success is however still 
lower than the WHO target of 90% (Stop TB Partnerships, 2006; WHO, 2006). 
 
The cure reported in this study appeared lower in comparison to the study by Jasmer et al. 
(2004) that indicated a very high cure of 98% among TB patients treated under DOTS in the 
USA. The study further reported a defaulter of 5.6% which is slightly higher than the national 
defaulter that was reported at 4% (MoHSS, 2013). The defaulter was however low compared 
to Castelnuovo’s (2010) findings of 11.3% to 29.6% as the defaulter in a number of sub-
Saharan African studies. Moreover, the TB mortality of 6.5% reported in this study appeared 
slightly higher than the reported national and district TB mortality (MoHSS, 2013). The 
treatment failure of 1.8% as reported in this study is slightly below the national TB treatment 
failure that was reported at 5% (MoHSS, 2013). The findings about treatment outcomes from 
this study are helpful in providing context specific information as well as for comparing these 
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treatment outcomes with the WHO recommendations and findings on treatment outcomes 
from elsewhere. 
 
5.4 Effects of treatment compliance on treatment outcomes  
 
The findings from this study suggest that treatment compliance seems to have an effect on 
treatment outcomes with compliance associated with treatment success. This was indicated in 
both phases of treatment and overall. In the initial phase of treatment, compliance was 
associated with treatment success as in the continuation phase and overall. Looking at the 
chi-squared test results (Table 9) that indicated a strong association, it is clear that those 
patients that complied with their treatment had higher treatment success than those that were 
non-compliant. These findings are in agreement with Gelmanova et al. (2006) who found that 
non-compliance with TB treatment has significant adverse effects for TB treatment outcomes. 
The findings also confirm that compliance with TB treatment is important to the success of 
TB control programmes because it promotes higher treatment success (Adane et al., 2013; 
Afns & Ji, 2010; Naidoo et al., 2013). 
 
5.5 Limitations 
 
Since the study has made use of secondary data, the findings are limited to the information 
that was available in the patients’ treatment cards. The factors affecting compliance were also 
limited to those documented in the patients’ treatment cards. However, the study findings are 
still useful in providing information about compliance and its distribution among 
demographic and clinical variables as well as its effects on treatment outcomes. Some data 
were also incomplete in some patients’ treatment cards particularly data on co-morbidities, 
side-effects, alcohol consumption and knowledge of TB through patient education 
verification. Though records with some missing data were included in the descriptive 
analysis, they were excluded from further analysis in order to prevent their effects on the 
study findings. Acknowledging these limitations allows for proper interpretation of the 
findings and avoidance of assumptions. 
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Summary 
 
Overall compliance and treatment success among adult PTB patients treated via DOTS in 
Windhoek District between 1st January 2013 and 31st December 2013 were higher than expected 
but slightly lower compared to the WHO recommended treatment compliance and success. 
Initial phase of treatment recorded higher treatment compliance, while compliance was slightly 
low in the continuation phase of treatment. Non-compliance recorded in this study was much 
lower than all the other studies. Continuation phase was identified to be the most problematic 
phase when it comes to compliance and these findings are in agreement with the literature. Age 
and type of area are associated with compliance and in the continuation phase of treatment while 
type of area is associated with overall compliance and this is also new contribution of 
knowledge. The findings from this study suggest that treatment compliance seems to have an 
effect on treatment outcomes. Treatment compliance is associated with treatment success in both 
phases of treatment and overall. The next Chapter (Chapter six) presents conclusions on the 
study and recommendations for practice and further research based on the study findings. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
Introduction 
 
This Chapter provides the conclusions from the study and recommendations for practice and 
further research about the effects of treatment compliance on treatment outcomes in Windhoek 
District.  
 
6.1 Conclusions 
 
The study conclusions are based on the study’s key findings and discussions. In determining the 
effects of treatment compliance on treatment outcomes for adult PTB patients treated via DOTS 
in Windhoek District in Namibia between the 1st January 2013 and 31st December 2013, the 
study investigated TB treatment compliance and measured the relationships between treatment 
compliance and patients’ characteristics. It also assessed the relationship between compliance 
and treatment outcomes. The study revealed some interesting findings about TB treatment 
compliance in Windhoek District. Overall treatment compliance of 89% for new PTB patients 
treated via DOTS in Windhoek District was reported in this study. This compliance was higher 
than expected but slightly lower than the WHO recommended 90% compliance. Compliance was 
also lower than desired at 88.1% in the continuation phase of treatment. However as supported 
by the literature, very high compliance (97.2%) was reported in the initial phase of treatment 
(Adane et al., 2013; Awofeso, 2008; Takarinda et al., 2012) It can be concluded that slightly 
lower than desired overall compliance in Windhoek District is likely due to the reduced 
compliance in the continuation phase of treatment. The continuation phase of treatment 
continues to appear to be a relatively problematic phase when it comes to TB treatment 
compliance; although relative to other contexts compliance is still good. Factors related to the 
increase in compliance in the initial phase of treatment and the reduced compliance in the 
continuation phase were not explored in this study. If not addressed the reduced compliance 
during continuation could lead to poor treatment outcomes such as prolonged infections, relapse, 
high TB mortality and drug resistant TB. These adverse outcomes may further increase the TB 
programme’s costs.  
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Treatment success (86.1%) among adult PTB patients treated via DOTS in Windhoek District 
was also higher than expected but slightly lower compared to the literature and WHO treatment 
success (90%). It can be concluded that Windhoek District is still below the WHO treatment 
success target.  
 
Type of area showed an overall significant association with compliance, as well as in the 
continuation phase of treatment while age showed a significant association with compliance in 
the continuation phase of treatment. Patients from rural areas were less likely to comply with 
their treatments compared to patients from other areas, while older adult patients aged 45+ years 
were more likely to comply with their TB treatment compared to young adults aged 15 – 34 
years. It can be concluded that older age 45+ years increase the chances of TB treatment 
compliance in the continuation phase of treatment while rural areas reduce the chance of TB 
treatment compliance in the overall and in the continuation phase of treatment.  
 
Non-compliance is associated with poor treatment outcomes while compliance is associated with 
treatment success. The study concludes that the effect of treatment compliance on treatment 
outcomes is that non-compliance causes poor treatment outcomes while compliance leads to 
better treatment outcomes.  
 
6.2 Recommendations 
 
The following recommendations emanate from the study’s conclusions. The recommendations 
should be used to improve compliance and its effects on treatment outcomes in the District and 
for further research. 
 
6.2.1 Recommendations to improve compliance in Windhoek District 
 
In order to increase compliance, decrease non-compliance and improve treatment outcomes in 
Windhoek District, the following recommendations are made for the consideration of the District 
Management Team and Programme Managers. 
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 Create awareness about the importance of TB treatment compliance at the community 
level and during all phases of treatment to enhance treatment compliance and improve 
treatment success. 
 District Management Team and the District TB Co-ordinators to consider additional or 
different mechanisms to support rural patients, young adults and all the patients in the 
continuation phase of treatment to increase their treatment compliance. 
 Create awareness about treatment compliance among TB patients and treatment 
supporters at the beginning of the treatment and in particular at the end of the initial 
phase and during the continuation phase to address reduced compliance during this phase.  
 Continuous support and monitoring and  to patients in the continuation phase of treatment 
from relatives, CB-DOT supporters, health facility-based treatment supporters and the 
District Management Team should be enforced  to ensure compliance in this phase. 
 Continuous support and monitoring of younger adults (15 – 34 years) in the continuation 
phase of treatment from relatives, DOTS supporters and the District Management Team 
should be enforced to ensure compliance among these age category in the continuation 
phase.  
 Strengthen the district’s CB-DOT by increasing CB-DOTS points and enhancing CB-
DOTS supporters’ capacity in terms of the number and skills. This is to ensure that 
patients from rural areas who might be challenged in accessing health care facilities 
treated under are well monitored and encouraged to comply with their treatment through 
CB-DOT. 
 Strengthen record keeping and ensure that all the important information about the patients 
are recorded completely and accurately in order to ensure proper monitoring of the 
patients and to ensure availability of data for future research. 
 
6.2.2 Recommendations for further research 
 
 Since this research was unable to provide a good measure about the factors influencing 
compliance, a prospective study involving interviewing TB patients as they start their TB 
treatment and following them up to the end of their treatment is required to ensure that all 
the factors influencing compliance are explored. 
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o Further studies should consider exploring the impacts of socio-economic factors 
on treatment compliance. 
o Study exploring kinds of psycho-social and logistic support that patients might 
find helpful from the health services when entering the continuation phase to 
ensure compliance is recommended. 
o Effects of demographic, socio-economic and clinical factors on treatment 
outcomes also need to be explored. 
o Reasons why older adults are more compliant and younger adults are less 
compliant with TB treatment in the continuation phase need further exploration. 
o Reasons why patients from rural areas are less compliant with their TB treatment 
also need to be investigated further. 
 
Summary 
 
Overall treatment compliance (89%) for new PTB patients treated via DOTS in Windhoek 
District were reported in this study. This compliance was higher than expected but slightly lower 
than the WHO recommended 90% compliance. Very high compliance (97.2%) were reported in 
the initial phase of treatment. Compliance was also lower than desired 88.1% in the continuation 
phase of treatment. It can be concluded that slightly lower than desired overall compliance in 
Windhoek District is likely due to the reduced compliance in the continuation phase of treatment. 
The continuation phase of treatment continues to appear to be a relatively problematic phase 
when it comes to TB treatment compliance; although relative to other contexts compliance is still 
good though it falls below the recommended compliance. If not addressed the reduced 
compliance during continuation could lead to poor treatment outcomes such as prolonged 
infections, relapse, high TB mortality and drug resistant TB. These adverse outcomes may 
further increase the TB programme’s costs. Windhoek District’s treatment success is below the 
WHO’s treatment success targets. Being an older adult, male, from urban areas, diagnosed with 
PTB smear positive, treated under health facility-based DOT increases the chances of 
compliance. While being older adults aged 45 – 54 years and patients from urban areas are more 
likely to comply with their treatment due to a number of factors. Non-compliant patients are 
more likely to have poor treatment outcomes than compliant patients while compliant patients 
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are more likely to have a treatment success than non-compliant patients. The District 
Management Team and TB Programme Managers are encouraged to use this study’s findings 
and recommendations in devising strategies required in increasing compliance, decreasing non-
compliance and improving treatment success. 
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APPENDICES 
Appendix A: Data Extraction Tool  
 
________________________________________________________ 
   UNIVERSITY OF THE WESTERN CAPE 
     School of Public Health 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
A. DEMOGRAPHIC INFORMATION 
1. Code number  
2. Age in years   
3. Sex 
3.1 Male 
3.2 Female 
4. Employment status 
4.1 Employed  
4.2 Unemployed 
4.3 Not recorded 
5. Residence: ____________________________________________________ 
6. Type of area:   
6.1 Urban  
6.2 Rural 
B. CLINICAL INFORMATION 
7. Diagnostic Classification  
7.1 Pulmonary TB smear positive 
7.2 Pulmonary TB smear negative 
7.3 Pulmonary TB no smear  
8. Type of DOTS (Enter code) 
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8.1 Health Facility DOTS:  
8.2 Community Based DOTS: 
8.3 Other: Specify     
DOTS codes: close relative (1); Guardian-relative, neighbor (2); Workplace (3); Health Facility (4); Community Health 
Worker (5); Other (6) specify 
9. HIV Status  
9.1 Positive 
9.2 Negative 
9.3 Unknown 
 
10. Anti-Tuberculosis Therapy 
10.1 Date Started 
10.2 Date ended 
10.3 Initial Phase: Dosages Taken          Dosages Missed 
10.4 Continuation Phase: Dosages Taken   Dosages Missed 
11. Compliance in Percentages (%)  Compliance (Enter compliance code) 
11.1 Initial Phase 
11.2 Continuation Phase 
11.3 Overall compliance  
Compliance classifications: good compliance 80% and above (1); moderate compliance 40% - 79% (2); poor compliance 39% 
and below (3). 
C. CO-MOBIDITIES AND SIDE-EFFECTS 
12. Any documented co-morbidity? If yes, specify. 
12.1 Pre-treatment:  Yes  No     ______________ 
12.2 2 months of treatment:  Yes  No    ______________ 
12.3 5 – 6 months of treatment: Yes    No    ______________ 
13. Other Medicines taken? If yes, specify: 
13.1 Pre-treatment:  Yes   No   
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13.2 2 months of treatment: Yes  No   
13.3 5 – 6 months of treatment: Yes  No   
14. Any documented alcohol consumption? 
14.1 Pre-treatment: Yes   No   
14.2 2 months of treatment: Yes  No   
14.3 5 – 6 months of treatment: Yes  No   
15. Any documented side effects? If yes, enter code and for other enter code and specify. 
15.1 Pre-treatment: Yes   No    ______________ 
15.2 2 months of treatment: Yes  No   ______________ 
15.3 5 – 6 months of treatment: Yes  No   ______________ 
Side effects codes: skin rash (1); Jaundice (2); Confusion (3); Visual impairment (4); Shock (5); Renal failure (6); Poor 
appetite (7); Nausea/Vomiting (8); Abdominal pain (9); Joints pain (10); Burning/numbness or tingling sensation in the 
hands or feet (11); Drowsiness (12); Other (13) specify. 
D. KNOWLEDGE ON TB 
16. Patient Education Verification 
 Pre-treatment At 2 months of 
treatment 
At 5-6 months of 
treatment 
Yes  No Not 
recorded 
Yes No Not 
recorded 
Yes No Not 
recorded 
16.1 Knowledge of what TB is?          
16.2 Knowledge on how TB is spread?          
16.3 Knowledge on how to avoid infecting 
others? 
         
16.4 Knowledge on how TB is treated?          
16.5 Knowledge of whether TB can be cured?          
16.6 Knowledge on TB treatment and 
treatment duration? 
         
16.7 Knowledge on the importance of taking          
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E. TREATMENT OUTCOME 
17. Treatment Outcome after 6 months of treatment 
17.1 Cured      
17.2 Treatment Completed 
17.3 Treatment failure before 5 months of treatment 
17.4 Treatment failure after 5 months of treatment  
17.5 Defaulted 
17.6 Transfer out 
17.7 Died 
 
 
 
 
 
TB medications every day? 
16.8 Knowledge on the difference between TB 
and HIV/AIDS? 
         
16.9 Knowledge on the importance of 
knowing one’s HIV status if infected with 
TB? 
         
16.10 Knowledge on the importance of having a 
DOTS supporter? 
         
16.11 Knowledge of the common side-effects 
and how they are handled? 
         
16.12 Knowledge of the serious side-effects 
that should be reported to the hospital 
immediately? 
         
16.13 Knowledge on whether TB can relapse?          
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Appendix B: Permission from University of the Western Cape Senate Research Committee  
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Appendix C: Permission request letter for the Permanent Secretary  
                 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
24 October 2014 
The Permanent Secretary 
Ministry of Health and Social Services 
Private Bag 13198 
Windhoek  
Namibia 
 
Dear Sir 
Re: Request for permission to conduct a study on the “Effects of treatment compliance on 
treatment outcomes for Pulmonary Tuberculosis patients on Directly Observed Treatment-
Short course in Windhoek District in Namibia”. 
I am Ester Ndahekelekwa Nepolo, a Masters of Public Health Student at the University of the 
Western Cape. I am asking for your permission to access patients’ information in conducting the 
above mentioned study because you are the person in charge of the Ministry of Health in which 
the study will be conducted. The study will be undertaken as a partial fulfilment for the 
completion of the Masters of Public Health Degree. 
The purpose of this study is to determine whether patients’ compliance with TB treatment 
through DOTS has got an effect on TB treatment outcomes. The study will look at the overall 
treatment compliance and to assess factors influencing compliance as well as relationship 
between compliance and different treatment outcomes for PTB patients on DOTS in Windhoek 
District. The results of this study could be used to contribute to the existing body of knowledge 
and provide context specific information on TB management in the District, which is crucial for 
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TB management and development of targeted strategies in promoting TB treatment compliance 
through DOTS in order to improve treatment success, prevent default, treatment failure and TB 
mortality.  
 
A quantitative retrospective study will be used in this study, making use of all patients’ records 
(patient treatment cards) of all new adult PTB cases of both sexes who were treated on DOTS in 
Windhoek District from 01 January 2013 to 31 December 2013. I will use the permission to 
access the District TB register where I will look at the eligible patients’ records for inclusion in 
the study. All eligible records will be included in the study.  
 
The TB treatment cards from the eligible files will then be collected for data collection using the 
data extraction tool that will require the following information: demographic information, 
clinical information such as type of DOT received and diagnostic classification, co-morbidities 
and side effects, patient education verification as well as and treatment outcome. The data 
collected will be analysed using Epi info 7 for data entry and analysis; to determine compliance 
with TB treatment, frequencies and proportions of risk factors as well as prevalence of different 
treatment outcomes. 
The data collection will take place at the District TB outpatient, where all the District records are 
kept. The data collection will take 3 – 4 weeks. Therefore I also request your permission to use 
the TB outpatient department space during data collection. Using the TB outpatient space will 
enable me to maintain the confidentiality of the information contained in the records and also to 
safe keep the records. To help protect patient’s confidentiality, the collected information will be 
kept at the safer place (locked cabinet), and the data will finally be stored in a password 
protected computer files. To maintain anonymity, no names will be included on the data 
abstraction tools, codes will be used instead and only the researcher will know those codes and 
no one else can link the information on the coded forms to any patient’s information. If we write 
a report or article about this research project, the identity of the patients will not be revealed.  
Since there will not be any direct interaction between the researcher and the patients’ whose files 
will be reviewed in the study, there are no known risks associated with this research project. The 
study findings will benefit the TB programme in devising targeted actions based on the study 
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findings. The study findings will be presented to the District Management Team as well as to the 
District TB programme coordinators. The Research Unit of the Ministry and the District will be 
provided with the copy of results that will be kept for future references. This research has been 
approved by the University of the Western Cape’s Senate Research Committee and Ethics 
Committee. 
If you have any questions about the research study itself, please contact me Ester Ndahekelekwa 
Nepolo at: P.O. Box 7647, Katutura, Namibia; Cell phone number +264 811244083, email 
address: eshaama80@gmail.com or my Supervisor: Dr. Lucia Knight, University of the Western 
Cape, Private Bag X17, Bellville 7535, Telephone: +27 21 959 2243, Email address: 
lnight@uwc.ac.za  
Thank you for considering my request. I have attached my research proposal and the data 
abstraction tool as well as the Ethical Clearance from University of the Western Cape’s Senate 
Research Committee and Ethics Committee. 
Kind regards, 
 
Ester Ndahekelekwa Nepolo 
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Appendix D: Permission request letter for the Khomas Health Regional Director 
                 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
24 October 2014 
The Regional Director 
Khomas Regional Health Directorate 
Ministry of Health and Social Services 
Private Bag 13198 
Windhoek  
Namibia 
 
Dear Madam 
Re: Request for permission to access patients’ information in conducting the study on 
“Effects of treatment compliance on treatment outcomes for Pulmonary Tuberculosis 
patients on Directly Observed Treatment-Short course in Windhoek District in Namibia”. 
I am Ester Ndahekelekwa Nepolo, a Masters of Public Health Student at the University of the 
Western Cape. I am asking for your permission to access patients’ information in conducting the 
above mentioned study because you are the person in charge of Khomas Health Regional 
Directorate in which the study will be conducted. The study will be undertaken as a partial 
fulfilment for the completion of the Masters of Public Health Degree. 
The purpose of this study is to determine whether patients’ compliance with TB treatment 
through DOTS has got an effect on TB treatment outcomes. The study will look at the overall 
treatment compliance and to assess factors influencing compliance as well as relationship 
between compliance and different treatment outcomes for PTB patients on DOTS in Windhoek 
 
 
 
 
 
 
76 
 
District. The results of this study could be used to contribute to the existing body of knowledge 
and provide context specific information on TB management in the District, which is crucial for 
TB management and development of targeted strategies in promoting TB treatment compliance 
through DOTS in order to improve treatment success, prevent default, treatment failure and TB 
mortality.  
 
A quantitative retrospective study will be used in this study, making use of all patients’ records 
(patient treatment cards) of all new adult PTB cases of both sexes who were treated on DOTS in 
Windhoek District from 01 January 2013 to 31 December 2013. I will use the permission to 
access the District TB register where I will look at the eligible patients’ records for inclusion in 
the study. All eligible records will be included in the study.  
 
The TB treatment cards from the eligible files will then be collected for data collection using the 
data extraction tool that will require the following information: demographic information, 
baseline information such as type of DOT received and diagnostic classification co-morbidities 
and side effects, patient education verification as well as and treatment outcome. The data 
collected will be analysed using Epi info 7 for data entry and analysis; to determine compliance 
with TB treatment, frequencies and proportions of risk factors as well as the prevalence of 
different treatment outcomes. 
The data collection will take place at the District TB outpatient, where all the District records are 
kept. The data collection will take 3 – 4 weeks. Therefore I also request your permission to use 
the TB outpatient department space during data collection. Using the TB outpatient space will 
enable me to maintain the confidentiality of the information contained in the records and also to 
safe keep the records. To help protect patient’s confidentiality, the collected information will be 
kept at the safer place (locked cabinet), and the data will finally be stored in a password 
protected computer files. To maintain anonymity, no names will be included on the data 
abstraction tools, codes will be used instead and only the researcher will know those codes and 
no one else can link the information on the coded forms to any patient’s information. If we write 
a report or article about this research project, the identity of the patients will not be revealed.  
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Since there will not be any direct interaction between the researcher and the patients’ whose files 
will be reviewed in the study, there are no known risks associated with this research project. The 
study findings will benefit the TB programme in devising targeted actions based on the study 
findings. The study findings will be presented to the District Management Team as well as to the 
District TB programme coordinators. The District will further be provided with the copy of 
results that will be kept for future references. The study has been approved by both the 
University of Western Cape Ethics committees and the Ministry of Health and Social Services 
Research Management Committee.  
If you have any questions about the research study itself, please contact me Ester Ndahekelekwa 
Nepolo at: P.O. Box 7647, Katutura, Namibia; Cell phone number +264 811244083, email 
address: eshaama80@gmail.com or my Supervisor: Dr. Lucia Knight, University of the Western 
Cape, Private Bag X17, Bellville 7535, Telephone: +27 21 959 2243, Email address: 
lnight@uwc.ac.za  
Thank you for considering my request. I have attached the approval letter from the Ministry of 
Health and Social Services through the Permanent Secretary’s office and the data abstraction 
tool. 
Kind regards, 
 
Ester Ndahekelekwa Nepolo 
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Appendix E: Permission request letter for the Intermediate Hospital Katutura’s Medical 
Superintendent  
                 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
24 October 2014 
The Medical Superintendent 
Intermediate Hospital Katutura 
Ministry of Health and Social Services 
Private Bag 13198 
Windhoek  
Namibia 
 
Dear Sir/Madam 
Re: Request for permission to access patients’ information in conducting the study on 
“Effects of treatment compliance on treatment outcomes for Pulmonary Tuberculosis 
patients on Directly Observed Treatment-Short course in Windhoek District in Namibia”. 
I am Ester Ndahekelekwa Nepolo, a Masters of Public Health Student at the University of the 
Western Cape. I am asking for your permission to access patients’ information in conducting the 
above mentioned study because you are the person in charge of Windhoek Health District in 
which the study will be conducted. The study will be undertaken as a partial fulfilment for the 
completion of the Masters of Public Health Degree. 
The purpose of this study is to determine whether patients’ compliance with TB treatment 
through DOTS has got an effect on TB treatment outcomes. The study will look at the overall 
treatment compliance and to assess factors influencing compliance as well as relationship 
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between compliance and different treatment outcomes for PTB patients on DOTS in Windhoek 
District. The results of this study could be used to contribute to the existing body of knowledge 
and provide context specific information on TB management in the District, which is crucial for 
TB management and development of targeted strategies in promoting TB treatment compliance 
through DOTS in order to improve treatment success, prevent default, treatment failure and TB 
mortality.  
 
A quantitative retrospective study will be used in this study, making use of all patients’ records 
(patient treatment cards) of all new adult PTB cases of both sexes who were treated on DOTS in 
Windhoek District from 01 January 2013 to 31 December 2013. I will use the permission to 
access the District TB register where I will look at the eligible patients’ records for inclusion in 
the study. All eligible records will be included in the study.  
 
The TB treatment cards from the eligible files will then be collected for data collection using the 
data extraction tool that will require the following information: demographic information, 
baseline information such as type of DOT received and diagnostic classification, diagnostic 
evaluation and monitoring of progress, co-morbidities and side effects, patient education 
verification as well as and treatment outcome. The data collected will be analysed using Epi info 
7 for data entry and analysis; to determine compliance with TB treatment, frequencies and 
proportions of risk factors as well as prevalence of different treatment outcomes. 
The data collection will take place at the District TB outpatient, where all the District records are 
kept. The data collection will take 3 – 4 weeks. Therefore I also request your permission to use 
the TB outpatient department space during data collection. Using the TB outpatient space will 
enable me to maintain the confidentiality of the information contained in the records and also to 
safe keep the records. To help protect patient’s confidentiality, the collected information will be 
kept at the safer place (locked cabinet), and the data will finally be stored in a password 
protected computer files. To maintain anonymity, no names will be included on the data 
abstraction tools, codes will be used instead and only the researcher will know those codes and 
no one else can link the information on the coded forms to any patient’s information. If we write 
a report or article about this research project, the identity of the patients will not be revealed.  
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Since there will not be any direct interaction between the researcher and the patients’ whose files 
will be reviewed in the study, there are no known risks associated with this research project. The 
study findings will benefit the TB programme in devising targeted actions based on the study 
findings. The study findings will be presented to the District Management Team as well as to the 
District TB programme coordinators. The District will further be provided with the copy of 
results that will be kept for future references. The study has been approved by the University of 
Western Cape Ethics committees, Ministry of Health and Social Services Research Management 
Committee through the Permanent Secretary’s office and by the Khomas Regional Health 
Director.  
If you have any questions about the research study itself, please contact me Ester Ndahekelekwa 
Nepolo at: P.O. Box 7647, Katutura, Namibia; Cell phone number +264 811244083, email 
address: eshaama80@gmail.com or my Supervisor: Dr. Lucia Knight, University of the Western 
Cape, Private Bag X17, Bellville 7535, Telephone: +27 21 959 2243, Email address: 
lnight@uwc.ac.za  
Thank you for considering my request. I have attached the approval letter from the Khomas 
Regional Health Director and the data abstraction tool. 
Kind regards, 
 
Ester Ndahekelekwa Nepolo 
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Appendix F: Permission from the Permanent Secretary 
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Appendix G: Permission from the Medical Superintended of Intermediate Hospital 
Katutura  
 
 
 
 
